EUROPEAN SOCIETY
FOR SEXUAL MEDICINE

17th CONGRESS OF THE EUROPEAN SOCIETY FOR SEXUAL MEDICINE

5 – 7 February 2015 | Copenhagen, Denmark

www.essm.org

FINAL PROGRAM



1995 – 2015

© Jenny Thompson – fotolia.com

Hosted by: Scandinavian Society for Sexual Medicine

Table of Content

Page

3 Welcome Address
4 ESSM History
5 ESSM Committees
6 ESSM Prizes and Awards
7 CME Accreditation
9 Structure of the Scientific Program
10 Scientific Program Schedule

Scientific Program
13 Thursday, 5 February 2015
20 Friday, 6 February 2015
25 Saturday, 7 February 2015

33 Poster Presentations
39 Cases that Matter Presentations
41 Workshops
45 General Information
49 Overview of Meeting Rooms
51 List of Exhibitors/Exhibition Plan
52 Acknowledgements
53 Industry Sessions
56 List of Chairpersons and Presenters

ESSM 2015 APP CONGRESS MOBILE®

Get the ESSM 2015 congress app for your smart phone now and experience the congress at your fingertips! Stop carrying around piles of paper and quickly find your way through the most up-to-date congress schedule. Just take the congress with you, wherever and whenever you want! The app is completely free and provides iPhone/iPad and android users at ESSM 2015 in Copenhagen with on-the-go access to the schedule and vital information around the congress. Powered by GLOBIT's acclaimed CONGRESS MOBILE® software.

Further information is given at
www.essm-congress.org/app

CONGRESS VENUE

Congress Venue
Bella Center
Center Boulevard 5
2300 Copenhagen S

CONGRESS AND EXHIBITION OFFICE

CPO HANSER SERVICE

Office Hamburg
Hanser & Co GmbH
Zum Ehrenhain 34
22885 Barsbüttel | Germany
Phone: +49–40–670 88 20
Fax: +49–40–670 32 83
Email: essm2015@cpo-hanser.de

ESSM SCIENTIFIC CHAIR

Maarten Albersen
Experimental Urology
University Hospitals Leuven
Leuven, Belgium
Email: ESSM_scientific@hotmail.com

ESSM SECRETARIAT

European Society for Sexual Medicine
Daniela Pajola
Via Ripamonti 129
20141 Milan | Italy
Phone: +39–025–6601 625
Fax: +39–027–0048 577
Email: admin@essm.org

Welcome Address

David Ralph

Jens Sønksen

Mikkel Fode

Dear Colleagues,

On behalf of the European Society for Sexual Medicine (ESSM) and the Scandinavian Society for Sexual Medicine (SSSM), it is a great pleasure for us to welcome you all to the 17th Congress of the ESSM in Copenhagen, 2015.

Copenhagen was the host to a very successful ESSM Congress in 2005, and it is a true honor to celebrate the 10 year anniversary with a return to the Danish capital city.

Furthermore it is a privilege that during the 2015 congress it is the 20 year Anniversary celebration of the European Society for Sexual Medicine (ESSM). To celebrate this occasion we would like to invite all delegates to an anniversary reception after the opening ceremony. Remembering the past 20 years will also continue throughout the meeting.

Copenhagen is a pulsating metropolitan capital as well as a historical oasis, which is home to the oldest monarchy in the world. You can reach Copenhagen Airport on non-stop flights from more than 140 destinations.

The ESSM Congress will be hosted at the Bella Center. The goals of the Congress will be both to deliver optimal scientific and educational programs and to promote the field of Sexual Medicine. The content of the Congress will cover topics regarding all sexes and all sexual orientations as well as state-of-the-art educational opportunities. The most recent innovative research will be highlighted. To achieve this, the faculty will include both renowned experts and up-coming stars in our field. The Local Organizing Committee will strive to make the importance of the Congress evident to the public and to the scientific and health care authorities. This is crucial because of the obvious co dependence between the people who develop and the people who perform treatments. Finally, we wish to create more networking opportunities for especially young researchers and health care providers with an interest in Sexual Medicine.

If you have time to enjoy the city during the Congress, a thousand year history awaits you in museums and open historical buildings throughout the city. For those who are more interested in modern trends, Copenhagen is also one of the world‘s leading design capitals.

We look forward to welcoming you to Copenhagen and together we will build a great ESSM Congress for 2015!

David Ralph, UK
ESSM President

Jens Sønksen, Denmark
Local co-chair

Mikkel Fode, Denmark
Local co-chair

ESSM History

ESSM PRESIDENT

David Ralph
St. Peter's Hospital and The Institute of Urology
London, United Kingdom

ESSM PRESIDENTS

1995–1997	Gorm Wagner, Denmark
1997–1999	Inigo Saenz de Tejada, Spain
1999–2001	John Pryor, United Kingdom
2001–2004	Dimitrios Hatzichristou, Greece
2004–2007	Francesco Montorsi, Italy
2007–2010	Ian Eardley, United Kingdom
2010–2014	Hartmut Porst, Germany
2014–2016	David Ralph, United Kingdom

ESSM CONGRESSES, VENUES AND CHAIRMEN

1995	Porto Carras, Greece Dimitrios Hatzichristou, Greece
1997	Madrid, Spain Inigo Saenz de Tejada, Spain
2000	Barcelona, Spain Halim Hattat, Turkey
2001	Rome, Italy Francesco Montorsi, Italy
2002	Hamburg, Germany Hartmut Porst, Germany
2003	Istanbul, Turkey Emre Akkus, Turkey
2004	London, United Kingdom David Ralph, United Kingdom
2005	Copenhagen, Denmark Petter Hedlund, Sweden Annamaria Giraldi, Denmark
2006	Vienna, Austria Siegfried Meryn, Austria
2007	Lisbon, Portugal Nuno Monteiro Pereira, Portugal
2008	Brussels, Belgium Joint Congress of ISSM/ESSM Eric Wespes, Belgium (ISSM) Claude Schulman, Belgium (ESSM)
2009	Lyon, France Béatrice Cuzin, France François Giuliano, France
2010	Malaga, Spain Antonio Martin Morales, Spain
2011	Milan, Italy Andrea Salonia, Italy
2012	Amsterdam, The Netherlands Luca Incrocci, The Netherlands
2014	Istanbul, Turkey Ates Kadioglu, Turkey
2015	Copenhagen, Denmark Mikkel Fode, Denmark Jens Sønksen, Denmark
2016	Madrid, Spain Ignacio Moncada, Spain Juan Ignacio Martinez-Salamanca, Spain

ESSM Committees

ESSM EXECUTIVE COMMITTEE

President	David Ralph, United Kingdom
Past President	Hartmut Porst, Germany
Secretary General	Natalio Cruz, Spain
Treasurer	Carlo Bettocchi, Italy
Advisory Board Representative	Mikkel Fode, Denmark
Chairman of the Scientific Committee	Maarten Albersen, Belgium
Chair of the Educational Committee	Yacov Reisman, The Netherlands
Members	Johannes Bitzer, Switzerland Selahittin Cayan, Turkey Selim Cellek, United Kingdom Ferdinando Fusco, Italy Zsolt Kopa, Hungary Arik Shechter, Israel Onder Yaman, Turkey
Ex Officio Members	
Editor of the ESSM Newsletter	Juan I. Martinez-Salamanca, Spain
Editors of the ESSM Website	Arik Shechter, Israel Pedro Vendeira, Portugal

ESSM EDUCATIONAL COMMITTEE

Chair	Yacov Reisman, The Netherlands
Members	Giovanni Corona, Italy Beatrice Cuzin, France Natalio Cruz, Spain John Dean, United Kingdom Ilan Gruenwald, Israel Evie Kirana, Greece Lior Lowenstein, Israel Fabrizio Palumbo, Italy Hartmut Porst, Germany Francesca Tripodi, Italy Michael Zitzmann, Germany

ESSM SCIENTIFIC COMMITTEE

Chair	Maarten Albersen, Belgium

Sub-Committee: Basic and translational science

Chair	Javier Angulo, Spain
Members	Delphine Behr-Roussel, France Fabio Castiglione, Italy Carla Costa, Portugal Ege Can Serefoglu, Turkey Christian Gratzke, Germany Petter Hedlund, Sweden

Sub-Committee: Male sexual health and dysfunction

Chair	Giovanni Corona, Italy
Members	Mikkel Fode, Denmark Patrick Jern, Finland Ates Kadioglu, Turkey Muammer Kendirci, Turkey Juan Ignacio Martinez-Salamanca, Spain Alexander Müller, Switzerland Salvatore Sansalone, Italy Paolo Verze, Italy

Sub-Committee: Female sexual health and dysfunction

Chair	Lior Lowenstein, Israel
Members	Andrea Burri, Switzerland Stephanie Cacioppo, Switzerland Annamaria Giraldi, Denmark Mijal Luria, Israel Linda Vignozzi, Italy

Sub-Committee: Psychosexual, gender and sexology

Chair	Marieke Dewitte, Belgium
Members	Walter Bouman, United Kingdom Cecilia Dhejne, Sweden Timo Ole Nieder, Germany Guy T'Sjoen, Belgium

Sub-Committee: Grants

Chair	Selim Cellek, United Kingdom
Members	Hartwig Büttner, Germany Peter Sandner, Germany Michael Wylie, United Kingdom

ESSM Committees/ESSM Prizes and Awards

ESSM LOCAL ORGANIZING COMMITTEE

Co-chairs Mikkel Fode, Denmark
Jens Sønksen, Denmark

Members Stefan Arver, Sweden
Torunn Bratvedt Larsen, Norway
Annamaria Giraldi, Denmark
Petter Hedlund, Sweden
Hans Jørgen Kirkeby, Denmark
Ellids Kristensen, Denmark
Lars Lund, Denmark
Alexander Schultz, Norway
Kerstin Sjögren Fugl-Meyer, Sweden
Trygve Talseth, Norway

LOCAL ADVISORY BOARD

Christina Damsted Petersen, Denmark
Urban Ekström, Sweden
Astrid Højgaard, Denmark
Mats Holmberg, Sweden
Birgitta Hulter, Sweden
Knut Klem, Norway
Esben Esther Pirelli Benestad, Norway

THE ESSM MEETING AWARDS

The best presentations will be awarded with EUR 2.000 by the ESSM's Award Committee.

1. Prize for the best presentation on psychosexual, gender and sexology
2. Prize for the best presentation on FSD (clinical)
3. Prize for the best presentation on MSD (preclinical)
4. Prize for the best presentation on MSD (clinical)

Please note that the author of the presentation must be present during the congress in Copenhagen.

F1000 POSTER PRIZES

The 'Faculty of 1000' has offered three best poster prizes during the 17th ESSM Congress 2015 in Copenhagen for pre-clinical, male clinical and female clinical research.

The prizes will comprise of:

1. A year's personal subscription to F1000Prime – "any award winner is clearly somebody who takes their research seriously and has excelled in their work. In order to harness this enthusiasm, we provide them with their own personal access to F1000Prime recommendations so that they can keep up to date with the top articles in the literature, and help in supplementing ongoing projects."

2. A free submission to F1000Research – "we provide the winners with the opportunity to publish their work rapidly with no hassle, giving them quick priority on their work, and enabling everyone in the field to benefit from their work right away."

3. A 'Faculty of 1000' certificate – "because it's nice to have a hard copy of the achievement for the award winner's record and curriculum vitae".

F1000 is composed of 5,000 Faculty Members – senior scientists and leading experts in all areas of biology and medicine – plus their associates. The Faculty recommends the most important articles, rating them and providing short explanations for their selections. More info can be found at http://f1000.com/.

A jury of Selim Cellek, Johannes Bitzer and Markus Margreiter has been composed to select the F1000 posters during the congress.

ESSM Prizes and Awards

ESSM RESEARCH GRANTS

Every year ESSM awards up to EUR 30,000 each for 3 – 4 research projects with a maximum duration of 18 months. Research Grants are open to all ESSM members who fulfill the eligibility criteria. The application deadline, eligibility criteria and terms and conditions of the grants can be found at the ESSM website. We will be hearing from some of the previous grant holders in Copenhagen meeting about their exciting and ground breaking research during the ESSM grant session scheduled on 5 February 2015, 11:30 – 12:30.

ESSM BASIC SCIENTIST TRAVEL GRANTS

These grants which all members of ESSM are welcome to apply for (providing that they meet the eligibility criteria), are intended to support basic scientists wishing to attend the ESSM Annual Congresses. ESSM recognises that basic scientists who are not actively engaged in clinical work in sexual medicine field may have difficulty finding sponsors to attend ESSM Annual Congresses. ESSM therefore has awarded a free registration and EUR 500 travel expenses to ten of its members for attending the annual congress.

THE ESSM PRESTIGE AWARDS

The Executive Committee of ESSM decided to establish two awards to be presented during the annual meetings of the society:

The ESSM Career Award

This award will be presented to a senior scientist who has made an outstanding contribution in the field. The Executive and Scientific Committees have selected the award winner. The award winner will be presented during the Opening Ceremony.

The ESSM Award of Excellence

This award is presented annually to a physician or scientist under 40 years of age (either in basic sciences or clinical practice) who has made recent exceptional achievement in the field.

ESSM AWARD WINNERS

Best Presentation Awards

1995 Christian Stief, Germany

1997 Paul F. Engelhardt, Germany
Francois Giuliano, France
Suks Minhas, United Kingdom

2000 Apostolos Apostolidis, Greece
F. Mumtaz, United Kingdom

2002 Annamaria Giraldi, Denmark
Andrea Salonia, Italy

2003 Stefan Ückert, Germany
Ilan Gruenwald, Israel
Mustafa Usta, Turkey
Alberto Briganti, Italy

2004 Byoung Ahn, Republic of Korea
Javier Angulo, Spain
Antonio Aversa, Italy

2005 Giovanni Corona, Italy
Elke Gizewski, Germany
Halim Hattat, Turkey
Attila Kun, Hungary
Sava Perovic, Serbia

2006 Fotini Ferenidou, Greece
Giulio Garaffa, Italy
Wayne Hellstrom, USA
Linda Vignozzi, Italy
Guido van Wingen, The Netherlands

2007 Stephanie Ortigue, France
Dara Lazar, Austria
Ignacio Moncada, Spain
Jun-Kyu Suh, Republic of Korea
Tolga Akman, Turkey

2008 David Ralph, United Kingdom
Judith Alder, Switzerland
Konstantinos Rokkas, Greece
K. Park, Republic of Korea
H. Gelez, France

2009 Andrea Russo, Italy
Gert Holstege, The Netherlands
Javier Angulo, Spain
Yoram Vardi, Israel
Jas Kalsi and Giulio Garaffa, United Kingdom

2010 José La Fuente Carvalho, Portugal
Elisa Bandini, Italy
Fulvio Colombo, Italy
Jonathan Greggain, Canada
Andrea Burri, United Kingdom

ESSM Awards/CME Accreditation

2011	Fabio Castiglione, Italy
	Jun-Kyu Suh, Republic of Korea
	Jacques Buvat, France
	Rosario Leonardi, Italy
2012	Silvia Vailati, Italy
	Annika Gunst, Finland
	Karl Beetson, United Kingdom
	Andrea Isidori, Italy
	Su-Yeon Jang, Republic of Korea
2014	Mustafa Faruk Usta, Turkey
	Ahmet Gokce, Turkey
	Lars Lund, Denmark
	Michael Krychman, USA
	Linda Vignozzi, Italy

Career Award

2002	John Pryor, United Kingdom
2003	Gorm Wagner, Denmark
2004	Giles Brindley, United Kingdom
	Ronald Virag, France
2005	Karl-Erik Andersson, Sweden
2007	Inigo Saenz de Tejada, Spain
2008	Vaclav Michael, Czech Republic
2009	Axel R. Fugl-Meyer, Sweden
2010	Hans Hedlund, Norway
2011	Jacques Buvat, France
2012	Yoram Vardi, Israel
2014	Antonio Martin-Morales, Spain
2015	Graham Jackson, United Kingdom

Award of Excellence

2002	Petter Hedlund, Sweden
2003	Selim Cellek, United Kingdom
2004	Stefan Ückert, Germany
2005	Javier Angulo, Spain
	Ekkehard W. Hauck, Germany
2006	Andrea Salonia, Italy
2007	Antonio Aversa, Italy
2008	Delphine Behr-Roussel, France
2009	Giovanni Corona, Italy
2010	Tillmann Krüger, Germany
2011	Stephanie Cacioppo, Switzerland
2014	Linda Vignozzi, Italy
2015	Carla Costa, Portugal

CME ACCREDITATION

The **17th Congress of the European Society for Sexual Medicine** is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The **17th Congress of the European Society for Sexual Medicine** is designated for a maximum of (or 'for up to') **18 hours** of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Programme of The Royal College of Physicians and Surgeons of Canada.

Participants interested in obtaining EACCME credits may contact the staff at the ESSM Booth in the exhibition Hall A1 on the last day of attendance in order to receive a printed copy of their accreditation certificate.

Structure of the Scientific Program

The scientific program is structured according to days. Per day it is structured by time and room. All presenters are listed by name and the title of their presentation

MASTER LECTURES

Master lectures of 30 minutes will be given by a distinguished and renowned expert and will be devoted to a specific topic of major interest.

ROUND TABLES

These sessions will usually last 90 minutes. Some of these sessions are scheduled for 60 minutes. They will focus on a particular topic and present the very latest data related to it. The round tables will include four or five papers and time for discussion.

WORKSHOPS – Lessons from the experts beyond the EBM (Evidence Based Medicine)

Workshops are designed for an interactive exchange of knowledge in the field of Sexual Medicine. During each workshop a short review of the accepted practice will be given following practical tips and tricks for the daily practice. The workshops will be conducted by a prominent, experienced speaker. The number of participants is limited, pre-registration is necessary. Hand-outs will be available online following to the respective workshop.

LIVE SURGERY

International experts will demonstrate cutting edge techniques and new tricks in a lively format. The surgery will be lively broadcasted from the Department of Urology of the Herlev Hospital, Copenhagen.

VIDEO SURGERY COURSE

The video surgery course will last 90 minutes, each video has a duration of 10 to 15 minutes. A panel of selected experts will present surgical videos showing different techniques and approaches and will discuss the details with the participants.

SYMPOSIA IN NATIONAL LANGUAGE

During the three congress days a dedicated room will be provided for symposia in national language by the National Affiliated Societies of the ESSM.

PODIUM SESSIONS

Podium sessions will present the best papers accepted for the congress and will focus on specific topics presenting the very latest findings in this field. Each session will last between 30 to 60 minutes. Presentations are limited to 4 minutes followed by 2 minutes of discussion.

HIGHLIGHTED POSTER TOURS

Authors were invited to submit abstracts on their latest research findings or important ongoing research. The highlighted poster tours were selected by the Scientific Committee based on a peer review of all abstract submissions. The most interesting posters are grouped by topic and presented in 30-minute moderated tours. Each tour will consist of a maximum of 7 posters in the same general field and will take place during the coffee breaks from Thursday to Saturday.

POSTER PRESENTATIONS

Authors were invited to submit abstracts on their latest research findings or important ongoing research as posters; these will be grouped into areas of research by the scientific committee. The poster exhibition in hall A1 is scheduled from Thursday, 5 to Saturday, 7 February 2015.

CASES THAT MATTER PRESENTATIONS

These presentations will present the accepted cases supported by an unrestricted educational grant. The purpose of the grant is to aid health care providers and researchers in the field in receiving clinically and scientifically current, accurate and relevant education in order to provide optimal care to patients. The presentations are disposed as posters in hall A1. The best 4 presentations have been selected for a 60-minute session, scheduled on Thursday, 5 February 2015.

INDUSTRY SPONSORED SESSIONS

Industry sponsored sessions organized by the industry in consultation with the scientific committee are considered for the congress days from Thursday to Saturday. These sessions are scheduled during the congress and will not interfere with the scientific program.

Scientific Program Schedule I Thursday, 5 February 2015

Time / Room	Auditorium 15 (Room 1)	Auditorium 10/11 (Room 2)	Auditorium 12 (Room 3)	Room 18/19 (Room 4)	Foyer/Hall A1
08:30					**Registration Counter** 07:30–18:00
	Congress Opening				
09:00	**RT-01** Populations studies in sexual dysfunction	**PS-01** Penile disorders and penile surgery	**WS-01** Premature ejaculation, delayed ejaculation and anejaculation		**Exhibition** 10:00–20:00
10:00	Break/HP-01 – HP-03		**WS-02** Erectile dysfunction: Difficult cases	**NS-01** Eurasian Andrology Summit – Update on male infertility (Turkish Society of Andrology) English language	**Highlighted Posters** 10:00–10:30 in the Poster Area **HP-01** Female sexual dysfunction **HP-02** Pre-clinical perspectives **HP-03** Genital reconstructive surgery
	ML-01 Mindfulness interventions for...				
11:00	**RT-02** ESSM-SMSNA friendship session: Penile rehabilitation: The fall of a myth?		**WS-03** Genital surgery – how to avoid complications		
12:00		**ESSM-01** ESSM Research Grants: Reports from previous winners...			
13:00	**SA-01** Industry sponsored symposium	Lunch Break		**NS-02** Update in andrology and sexology SIA (Società Italiana di Andrologia) and FISS (Italian Federation of Scientific Sexology) Italian language	**Poster Exhibition** 10:00–20:00
14:00	**VS-01** Industry sponsored video session	**RT-03** Novel approaches to psychotherapy – EFS and ESSM interactive symposium	**ESSM-02** Resident's corner		
15:00		**RT-04** Female genital disorders and sexual health			
16:00	**CM-01** Industry sponsored case session	**PS-03** Psychosexual issues and management	**PS-02** ED: Risk factors and medical management	**NS-03** SFMS/AIUS French Societies: Actualités et controverses French language	
	ML-02 Pornography. What does it do for sex...				
17:00		**ML-03** History of ESSM			
18:00	ESSM Opening Ceremony				
18:30	Networking Reception in the exhibition area from 18:30–20:00				

floorplan see page 49

ABBREVIATIONS

RT	–	Round Table
ML	–	Master Lecture
WS	–	Workshop
VS	–	Video Session
LV	–	Live Surgery Session
ESSM	–	ESSM Session
PS	–	Podium Session
CM	–	Case Session
NS	–	National Session
SA	–	Satellite Symposium

Friday, 6 February 2015 | Scientific Program Schedule

Time \ Room	Auditorium 15 (Room 1)	Auditorium 10/11 (Room 2)	Auditorium 12 (Room 3)	Room 18/19 (Room 4)	Foyer/Hall A1
08:30					**Registration Counter** 08:00–18:00 **Exhibition** 08:30–17:00
09:00	**LV-01** Industry sponsored live surgery	**RT-05** Paraphilias and BDSM in sexual medicine	**WS-04** Hormonal difficulties in men and women		
10:00		Break/HP-04			**Highlighted Posters** 10:00–10:30 in the Poster Area **HP-04** Psychosexual issues and management
11:00		**RT-06** Industry sponsored round table	**WS-05** Infertility and sexuality	**NS-04** AIUS/SFMS French Societies: New issues surrounding sexuality English language	
12:00		**ML-04** Award of Excellence			**Poster Exhibition** 08:30–17:00
13:00	**SA-02** Industry sponsored symposium	Lunch Break			
14:00	**RT-07** The dual model in transgender care	**RT-08** Toys and vibratory devices for joy and medical need	**PS-04** Ejaculatory disorders, hormones and prostate diseases	**NS-05** MESSM – Middle East Society for Sexual Medicine English language	
15:00	**ML-05** Sex addiction: Moral...	Break/HP-05, HP-06			**Highlighted Posters** 15:30–16:00 in the Poster Area **HP-05** Peyronie's disease **HP-06** Surgical treatment of male sexual dysfunction
16:00	**RT-16** Industry sponsored round table	**RT-09** Is there a future for medical therapy of Peyronie's disease?	**RT-10** Neurotransmitters, mood regulation and sexual behavior		
17:00					
18:00	ESSM Annual Business Meeting				
18:30					

Scientific Program Schedule I Saturday, 7 February 2015

Time / Room	Auditorium 15 (Room 1)	Auditorium 10/11 (Room 2)	Auditorium 12 (Room 3)	Room 18/19 (Room 4)	Foyer/Hall A1
08:30					**Registration Counter** 08:00–18:00 **Exhibition** 08:30–17:00 **Highlighted Posters** 10:00–10:30 in the Poster Area **HP-07** Ejaculatory disorders **HP-08** Risk factors and medical management I **HP-09** Hormones and male sexual health **Poster Exhibition** 08:30–17:00 **Highlighted Posters** 15:30–16:00 in the Poster Area **HP-10** ED risk factors and medical management II **HP-11** Prostatic disease and male sexual health
09:00	**VS-02** Complex reconstructive and plastic genital surgery	**RT-11** Testosterone substitution and male sexual health	**PS-08** Late breaking abstracts **WS-06** Vulvodynia, vestibulodynia and sexual pain disorders	**NS-06** ASESA – Asociacón Espagnola de Andrología/SPA – The Portuguese Society of Andrology Spanish language	
10:00	Break/HP-07 – HP-09				
11:00	**ML-06** ESSM: Two decades of...				
12:00	**RT-12** Are male factor infertility and male sexual dysfunction linked?	**PS-05** Sexual diversity and gender dysphoria	**WS-07** How to improve patient satisfaction and compliance **PS-09** Late breaking abstracts		
13:00	Lunch Break				
14:00	**RT-13** Debate: Testosterone supplementation: Safe for the heart?	**PS-06** Female sexual dysfunction	**PS-07** Basic science and translational research	**NS-07** SSSM – Scandinavian Society for Sexual Medicine English language	
15:00	**ML-07** What happened to good old Masters &...				
16:00	Break/HP-10, HP-11				
17:00	**RT-14** Incontinence and FSD	**RT-15** Panel discussion: Sexual side-effects of BPH treatment: Practical implications and prevention			
18:00		Closing Ceremony			
18:30					

CONGRESS OPENING

08:30–08:45 **Auditorium 15**

Chairs: Jens Sønksen, Denmark
Mikkel Fode, Denmark

PS-01 PODIUM SESSION

08:30–10:00 **Auditorium 10/11**

Penile disorders and penile surgery

Chairs: Carlo Bettocchi, Italy
Fulvio Colombo, Italy

011 **Safety and effectiveness of collagenase clostridium histolyticum (CCH) treatment in EU patients with Peyronie's disease: A comparison of EU enrolled subjects versus all subjects enrolled in a phase 3 open-label study**
David Ralph, United Kingdom
L. A. Levine, M. K. Gelbard, H. Olivecrona, G. Liu, J. P. Tursi, B. Cuzin, H. Porst, I. Moncada, V. Mirone

012 **Meaningful change in Peyronie's disease following treatment with collagenase clostridium histolyticum: Results from two large double-blind, randomized, placebo-controlled phase 3 studies**
Cully C. Carson, USA
M. Gittleman, R. B. W. Tan, H. Olivecrona, J. P. Tursi, T. M. Smith, G. J. Kaufman, N. A. Jones, W. J. G. Hellstrom

001 **Idiopathic partial thrombosis is associated with cycling and the presence of a fibrous web on MRI**
Emmanuel Weyne, Belgium
C. Schillebeeckx, C. Jamaer, P. D´Hulst, G. Bozzini, R. Grünert, P. Hoebeke, S. Joniau, M. Albersen

002 **Delay of surgical treatment of penile fracture results in poor functional outcome: Results from a large retrospective multicenter European study**
Giorgio Bozzini, Italy
M. Albersen, J. Romero Otero, M. Mergreiter, E. Garcia Cruz, A. Mueller, C. Gratzke, E.C. Serefoglu, J. I. Martinez Salamanca, P. Verze

003 **Surgical outcomes and patients: Satisfaction with suprapubic phalloplasty**
Jean-Etienne Terrier, France
F. Courtois, A. Ruffion, N. Morel journel

004 **Metaidoioplasty: Alternative for sex reassignment surgery in female-to-male transsexuals. Evaluation of patients' satisfaction by a new questionnaire**
Corinne Palamara, France
N. Morel Journel, A. Ruffion

005 **Superficial excision of glans epithelium for penile cancer and covering with TachoSil®**
Ralf Herwig, Austria
S. Sansalone

013 **Sexual function after surgical treatment for penile cancer: Which organ sparing approach gives the best results?**
Omid Sedigh, Italy
M. Falcone, C. Ceruti, M. Timpano, M. Falcone, F. Kuehhas, M. Preto, M. Sibona, B. Frea, L. Rolle

006 **Personal experience using STAGE technique for congenital penile curvature**
Luca Mavilla, Italy
R. U. Roman Urological Association

007 **How to improve extracorporeal shock wave therapy in the management of patients with Peyronie's disease? Results from a randomized trial comparing plaque injection either with a saline solution or with a hydrocortisone solution**
Maxime Sempels, Belgium
R. Andrianne, D. Waltregny, L. Coppens

008 **Does early insertion of a malleable prosthesis still allow later upsizing of cylinders in patients with ischemic priapism?**
Evangelos Zacharakis, United Kingdom
F. Deluca, A. Raheem, G. Garaffa, A. Muneer, D. Ralph

009 **Implant of an intracorporal phantom in order to prevent penile shortening after penile prosthesis removal due to prosthetic device infection or distal urethral erosion**
Nicolas Morel-Journel, France
J. E. Terrier, A. Simonato, A. Ruffion, M. Ennas

010 **Penile lengthening and widening without graft according to a modified sliding technique**
Franklin Kuehhas, Austria
P. Egydio

WS-01 WORKSHOP

08:30–10:00 **W** **Auditorium 12**

Premature ejaculation, delayed ejaculation and anejaculation

Expert: Marcel D. Waldinger, The Netherlands
Chair: Ege Can Serefoglu, Turkey

W Limited seats, pre-registration necessary/
Full description see page 41

Scientific Program I Thursday, 5 February 2015

RT-01 ROUND TABLE

08:45–10:00 **Auditorium 15**

Populations studies in sexual dysfunction

Chairs: Ian Eardley, United Kingdom
Antoine Faix, France

001 **NATSAL: Changes in sexual attitudes and lifestyles over time**
Kaye Wellings, United Kingdom

002 **SEXPERT: Sexual health and dysfunctions in 2015**
Els Elaut, Belgium

003 **EMAS: Sexual function and attitudes in the aging male**
Giovanni Corona, Italy

004 **Sexual dysfunction in patients with chronic diseases**
Ellids Kristensen, Denmark

NS-01 NATIONAL SYMPOSIUM

09:00–12:00 **Room 18/19**

Eurasian andrology summit: Update on male infertility – section I

Organizers: Ates Kadioglu, Turkey
Selahittin Cayan, Turkey

Chair: David Ralph, United Kingdom

001 **Robotic assisted andrological surgery: An update**
Ahmet Gökçe, Turkey

002 **m-TESE: Current strategies to improve sperm harvesting**
Ates Kadioglu, Turkey

003 **Success of epididymovasostomy: Comparison of different microsurgical techniques**
Natalio Cruz, Spain

004 **Approach to the patients with Klinefelter Syndrome from adolescent to reproductive age**
Raj Nigam, United Kingdom

Eurasian andrology summit: Update on male infertility – section II

Chairs: Natalio Cruz, Spain
Zsolt Kopa, Hungary
Pepe Cardoso, Portugal
Ilham Ahmadov, Azerbaidshan

001 **Adolescent varicocele: An update**
Selahittin Cayan, Turkey

002 **Male genital infections current diagnosis and treatment modalities**
Zsolt Kopa, Hungary

003 **Genetics and epigenetics concern of the patients undergoing ICSI**
Pedro Vendeira, Portugal

004 **Male reproductive dysfunctions and co-morbidities (metabolic syndrome, obesity, cancer)**
Giovanni Corona, Italy

English language only

10:00–10:30 BREAK

HP-01 HIGHLIGHTED POSTER TOUR

10:00–10:30 **Hall A1**

Female sexual dysfunction

Chairs: Torunn Bratvedt Larsen, Norway
Mijal Luria, Israel

001 **Female sexual function of brazilian overweight pregnant women**
Meireluci Ribeiro, Brazil
M. Nakamura, M. R. Torloni, M. Scanavino, R. Mattar

002 **The variability of coital orgasm in a sample of Italian women**
Roberto Bernorio, Italy
G. Polloni, G. Mori, A. Prunas, S. Di Santo

003 **Treatment of female arousal and orgasmic complaints in a female cancer population treated with Zestra®: A topical applied blend of botanical oils**
Michael Krychman, USA
B. Damaj, M. Hachicha, S. Kellogg

004 **The influence of breast reconstruction on sexual well-being after prophylactic mastectomy from the patients perspective: Analyses of depth interviews for improving health care**
Rieky Dikmans, Netherlands
R. Zwinkels, M.-B. Bouman, M. Mullender

005 **Effects of low frequency bullet vibrators on the clitoral orgasm and sexual lives of Turkish women**
Umit Sayin, Turkey
A. Kocaturk, T. Arisal, I. Dedecan, M. Arisal

006 **How do people feel about self-masturbation? Findings from a real-life survey in outpatients**
Alessandro Serino, Italy
E. Ventimiglia, P. Capogrosso, L. Boeri, G. La Croce, A. Pecoraro, M. Paciotti, I. Camozzi, M. Salonia, F. Montorsi, A. Salonia, G. La Croce

007 **Some socio-cultural aspects of etiology, prevalence and treatment of vaginismus in Georgia**
Zurab Marshania, Georgian

HP-02 HIGHLIGHTED POSTER TOUR

10:00–10:30 **Hall A1**

Pre-clinical perspectives

Chairs: Alexander Müller, Switzerland
Anthony J. Bella, Canada

001 **Expression and distribution of key mediators of the cyclic GMP pathway in the human clitoris - relation to the phosphodiesterase type 5 (PDE5)**
Stefan Ückert, Germany
M. Oelke, M. Kuczyk, K. Albrecht, P. Hedlund

002 **Expression and distribution of cannabinoid receptors in the human seminal vesicles**
Stefan Ückert, Germany
G. la Croce, A. Bettiga, F. Montorsi, M. Kuczyk, P. Hedlund

003 **Estrogen mediates metabolic syndrome-induced erectile dysfunction: A study in the rabbit**
Linda Vignozzi, Italy
S. Filippi, P. Comeglio, I. Cellai, A. Morelli, M. Maggi

004 **Increased vulnerability of corpus cavernosum to aging-induced endothelial dysfunction in rats**
Mariam El Assar, Spain
A. Fernández, A. Sánchez-Ferrer, S. Gabancho, J. M. Sánchez-Puelles, L. Rodríguez-Mañas, J. Angulo

005 **A novel dopamine reuptake inhibitor, NS18313 induces spontaneous erections in rats**
Simon Comerma Steffensen, Denmark
A. Kun, D. Peters, G. Munro, U. Simonsen

006 **The treatment of pomegranate juice restored erectile dysfunction in diabetic rats**
Didem Yilmaz, Turkey
S. Gur, E. Onal, T. Bastaskin, E. Kaya, D. Yilmaz

HP-03 HIGHLIGHTED POSTER TOUR

10:00–10:30 **Hall A1**

Genital reconstructive surgery

Chairs: Muammer Kendirci, Turkey
Mark-Bram Bouman, The Netherlands

001 **10 years single center experience in male to female sex reassignment surgery**
Alessandro Franceschelli, Italy
G. Gentile, F. Colombo

002 **Erectile function in men with failed hypospadias repair**
Chris Gonzalez, Italy
S. Sansalone, V. Iacovelli, G. Barbagli, G. Romano, G. Vespasiani, C. Loreto

003 **Sigmoid vaginoplasty and its impact on psycho-social and sexual life in patients with vaginal agenesis**
Vladimir Kojovic, Serbia
M. Bizic, M. Majstorovic, B. Stojanovic, L. Labus, D. Stanojevic, M. Djordjevic

004 **Patient reported outcomes for metoidioplasty**
Franklin Kuehhas, Austria
F. De Luca, M. Spilotros, S. Richardson, G. Garaffa, D. Ralph, N. Christopher

005 **Buried penis in adults: Presentation, surgical techniques and outcome**
Tet Yap, United Kingdom
M. Chocolaty, F. Spitaleri, A. Raheema, N. Christopher, G. Garaffa, S. Minhas, D. Ralph

006 **Our experience of nontransecting anastomotic bulbar urethroplasty**
Badri Gvasalia, Russia
B. Gvasalia, A. Kochetov, R. Abramov, V. Parshin, A. Borshevetskiy, S. Roslik

007 **Deviation of the erect straight penis**
Osama Shaeer, Egypt

WS-02 WORKSHOP

10:00–11:00 W **Auditorium 12**

Erectile dysfunction: Difficult cases

Expert: Dimitris Hatzichristou, Greece
Chair: Ilan Efraim Gruenwald, Israel

ML-01 MASTER LECTURE

10:30–11:00 **Auditorium 15**

Mindfulness interventions for treating sexual dysfunction: The science of finding focus in a multitask world

Chair: Marieke Dewitte, Belgium
Speaker: Lori Anne Brotto, Canada

RT-02 ROUND TABLE

11:00–12:15 **Auditorium 15**

ESSM-SMSNA friendship session: Penile rehabilitation: The fall of a myth?

Chairs: Anthony J. Bella, Canada
Lawrence Scott Hakim, USA

001 **Announcement of a new SMSNA and ESSM short visit grant**
Selim Cellek, United Kingdom

W Limited seats, pre-registration necessary/
Full description see page 41

Scientific Program I Thursday, 5 February 2015

002 **Announcement of a new SMSNA and ESSM short visit grant**
Trinity Bivalacqua, USA

003 **Pathophysiology of erectile dysfunction after nerve sparing radical prostatectomy: When does it become irreversible?**
Trinity Bivalacqua, USA

004 **Penile rehabilitation: What the clinical evidence tells us**
John P. Mulhall, USA

005 **Discrepancies between clinical and basic science studies: It is time to stop, think and start again**
Fabio Castiglione, Italy

006 **The future is now: Upcoming treatment targets for cavernous nerve injury induced ED**
Emmanuel Weyne, Belgium

WS-03 WORKSHOP

11:00–12:00 W **Auditorium 12**

Genital surgery – how to avoid complications

Expert: David Ralph, United Kingdom
Chair: Fabrizio Palumbo, Italy

001 **Peyronie's surgery. Indications, expectations and consent. Complication prevention – shortening, recurrent curvature, ED, foreskin issues, sutures**
Giulio Garaffa, United Kingdom

002 **Penile prosthesis. Indications, expectations and consent. Complication prevention – infection, erosion, positioning, revision surgery, deformities**
Fabrizio Palumbo, Italy

003 **Penile reconstruction. Complication prevention in – augmentation surgery, skin grafting, circumcision**
David Ralph, United Kingdom

ESSM-01 ESSM SESSION

11:15–12:30 **Auditorium 10/11**

ESSM Research Grants: Reports from previous winners & and new funding opportunities

Chair: Selim Cellek, United Kingdom

001 **Metformin increases adenosine signalling in corpora cavernosa: An experimental study in an animal model of metabolic syndrome**
Linda Vignozzi, Italy

002 **Modulation of adrenergic system as a novel strategy for the treatment of ED induced by cavernous nerve injury**
Javier Angulo, Spain

003 **The role of epigenetic factors in development and maintenance of female sexual problems**
Myriam Leupin, Switzerland

004 **Low-intensity extracorporeal shockwaves for ED: How does it work?**
Delphine Behr-Roussel, France

005 **New ESSM grant schemes and tips for applications**
Selim Cellek, United Kingdom

12:30–13:30 BREAK

SA-01 INDUSTRY SPONSORED SYMPOSIUM

12:30–13:30 **Auditorium 15**

see page 53

NS-02 NATIONAL SYMPOSIUM

12:30–15:30 **Room 18/19**

Update in andrology and sexology: SIA (Società Italiana di Andrologia) and FISS (Italian Federation of Scientific Sexology)

Introduction
Carlo Bettocchi, Italy
Giamo Franco, Italy
Roberta Rossi, Italy

Chirurgia andrologica e sessuologia clinica

Discussant: Giorgio Del Noco, Italy
Moderators: Giamo Franco, Italy
Roberta Rossi, Italy

Il registro interno dei sessuologi FISS
Adele Fabrizi, Italy

Registro SIA implantologia protesica peniena
Edoardo Pescatori, Italy

Discussione

La valutazione olistica del Paziente nella chirurgia andrologica

Il chirurgo, oltre la tecnica
Fulvio Colombo, Italy

Il sessuologo ed il counselling sessuale
Elena Vittoria Longhi, Italy

Discussione

W Limited seats, pre-registration necessary/
Full description see page 42

Andros, Kronos e Kairos: Tailoring sessuologico in andrologia
Discussant: Giuseppe La Pera, Italy
Moderators: Domenico Trotta, Italy
Fabrizio Scroppa, Italy

Andros e Kairos nella Disfunzione Erettile
Ciro Basile Fasolo, Italy

Andros e Kronos nella Disfunzione Erettile
Nicola Mondaini, Italy

DE e interazione sessuale disfunzionale nella coppia: strategie di counselling
Roberto Bernorio, Italy

Andros, Kronos e Kairos nella Eiaculazione Precoce
Poalo Verze, Italy

La terapia sessuologica per l'EP come potenziamento dell'approccio farmacologico
Roberta Rossi, Italy

Discussione

Italian language only

VS-01 INDUSTRY SPONSORED VIDEO SESSION

13:30–15:30 Auditorium 15

see page 53

RT-03 ROUND TABLE

13:30–15:00 Auditorium 10/11

Novel approaches to psychotherapy – EFS and ESSM interactive symposium
Chairs: Salvatore Caruso, Italy
Paraskevi-Sofia Kirana, Greece

001 **EFS/ESSM: Contemporary psychosexology: Re-examining the biopsychosocial model**
Francesca Tripodi, Italy

002 **EFS: Cognitive behaviour interventions for sexual dysfunction**
Pedro Nobre, Portugal

003 **ESSM: Impact of mindfulness interventions on sexual arousal**
Marieke Dewitte, Belgium

004 **EFS: E-health: Cost-efficacy and usefulness in the sexology practice**
Kevan Wylie, United Kingdom

ESSM-02 ESSM SESSION

13:30–15:30 Auditorium 12

Resident's corner
Chair: Mikkel Fode, Denmark

001 **ESRU: Sexual function after testicular cancer**
Christian Ruf, Germany

002 **ENTOG: Sexual medicine during training in obstetrics and gynaecology across Europe**
Anna Aabakke, Denmark

003 **EFPT: Sexual health in the psychiatry training across Europe**
Mariana Pinto da Costa, Portugal

004 **EYES: Working together for andrology: Implementing the novel curriculum for andrology**
Gesthimani Mintziori, Greece

005 **Lack of orgasm in a postmenopausal woman**
Sarah Wåhlin-Jacobsen, Denmark

006 **Adding life to years and not just years to life: Cancer and sexuality**
Yacov Reisman, The Netherlands

RT-04 ROUND TABLE

15:00–16:00 Auditorium 10/11

Female genital disorders and sexual health
Chairs: Astrid Højgard, Denmark
Lior Lowenstein, Israel

001 **Vulvodynia and vaginismus: Similarities and differences and why they belong together?**
Mijal Luria, Israel

002 **Impact of contraceptives on female sexuality, genital arousal and vulvodynia**
Johannes Bitzer, Switzerland

003 **Persistent genital arousel is it a subtype of vulvodynia?**
Atef R. Markos, United Kingdom

004 **Treatment modalities for sexual pain disorders**
Christina Damsted Petersen, Denmark

Scientific Program I Thursday, 5 February 2015

CM-01 INDUSTRY SPONSORED CASE SESSION

15:30–16:30 **Auditorium 15**

see page 53

PS-02 PODIUM SESSION

15:30–17:00 **Auditorium 12**

ED: Risk factors and medical management

Chairs: Andrea Salonia, Italy
Alexander Schultz, Norway

001 **Erectile dysfunction is common among men with acromegaly and is associated with morbidities related to GH excess rather than to a direct GH effect on erectile function**
Francesco Lotti, Italy
V. Rochira, D. Santi, E. Maseroli, A. Balestrieri, A. Peri, M. Maggi, G. Corona

002 **Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all cause mortality**
Adrian Heald, United Kingdom
G. Hackett, D. Hutchings

003 **Severe obstructive sleep apnea syndrome and erectile dysfunction: A prospective randomised study to compare sildenafil versus nasal continuous positive airway pressure**
Antonio Luigi Pastore, Italy
G. Palleschi, L. Silvestri, A. Gallo, G. Pagliuca, F. Nobili Benedetti, A. Carbone

004 **Sexual function in men who underwent percutaneous transluminal coronary angioplasty for acute myocardial infarction**
Cezary Golawski, Poland
K. Nowosielski, R. Kowalczyk, J. Syska-Suminska, M. Dluzniewski

005 **Erectile function after radical prostatectomy: Do patients return to baseline?**
Mikkel Fode, Denmark
A. Frey, H. Jakobsen, J. Sønksen

006 **Robot-assisted radical prostatectomy is associated with faster and greater recovery from orgasm associated incontinence**
Paolo Capogrosso, Italy
A. Serino, E. Ventimiglia, L. Boeri, G. La Croce, G. Castagna, G. Gandaglia, E. Farina, A. Briganti, F. Montorsi, A. Salonia

007 **The effect of „early“ vs. „late“ administration of low-dose tadalafil on nocturnal penile tumescense in the acute phase after nerve-sparing radical prostatectomy**
Andreas Bannowsky, Germany
S. Ückert, D. Osmonov, H. van Ahlen

008 **Evaluation of male sexual dysfunction after implementation of robot assisted surgery for rectal cancer: A single center study**
Amalie Schmiegelow, Denmark
I. Gögenur, M. Brohom, M. Fode

009 **Erectile dysfunction shock wave therapy (EDSWT) improves hemodynamic parameters in patients with vasculogenic erectile dysfunction (ED): A triplex-based sham-controlled trial**
Dimitrios Kalyvianakis, Greece
D. Hatzichristou

010 **Left ventricular geometry and the severity of erectile dysfunction; a ventriculoarterial interaction underneath the erectile disorder**
Athanasios Angelis, Greece
C. Vlachopoulos, N. Ioakimidis, K. Rokkas, M. Abdelrasoul, Z. Kratiras, K. Makarounis, D. Rompolis, C. Fasoulakis, D. Tousoulis

011 **Cardiovascular risk associated with testosterone boosting medications**
Elisa Maseroli, Italy
G. Corona, G. Rastrelli, A. M. Isidori, A. Sforza, E. Mannucci, M. Maggi

012 **Prevalence of sexual desire and satisfaction among patients with screen-detected diabetes and impact of intensive multifactorial treatment. Results from the ADDITION-Denmark study**
Mette B. Pedersen, Denmark
M. Davidsen, A. Giraldi, E. M. Kristensen, T. Lauritsen, A. Sandbaek, M. Charles

PS-03 PODIUM SESSION

16:00–17:00 **Auditorium 10/11**

Psychosexual issues and management

Chairs: Francesca Tripodi, Italy
Lori Anne Brotto, Canada

001 **Body image disturbance, sexual functioning and hormonal levels: A longitudinal study in anorexia nervosa patients**
Giovanni Castellini, Italy
L. Vignozzi, A. Fisher, L. Lelli, L. Godini, M. Maggi, V. Ricca

003 **An integrated approach with vardenafil orodispersible (v) and cognitive-behavioral sex therapy (CBST) for the treatment of erectile dysfunction (ED)**
Valentina Boddi, Italy
H. Casale, G. Rastrelli, G. Corona, M. Maggi

004 **Gender identity, paraphilic behaviours and autistic traits and in subjects with klinefelter syndrome**
Alessandra Daphne Fisher, Italy
E. Fanni, H. Casale, G. Castellini, E. Maseroli, G. Balercia, A. Oppo, A. Pizzocaro, D. Dèttore, V. Ricca, M. Maggi

005 **Womens endorsements of models of sexual response – correlates and predictors**
Krzysztof Nowosielski, Poland
B. Wrobel, R. Kowalczyk

006 **Medicalization of sexology**
Elsa Almås, Norway

NS-03 NATIONAL SYMPOSIUM

15:30–17:30 **Room 18/19**

Actualités et controverses en médicine sexuelle: Traitement par testostérone et risques cardio-vasculaires (SFMS/AIUS)

001 **Pourquoi les alertes récentes?**
Beatrice Cuzin, France

002 **Qu'en est-il réellement?**
Pierre Desvaux, France

Actualités et controverses en médicine sexuelle: Réflexion autour de l'éjaculation prématurée (SFMS/AIUS)

003 **Les définitions récentes de l'EP: Leur intérêt et leurs limites**
André Corman, France

004 **Les classifications actuelles de l'EP: Sont-elles utiles à sa prise en charge?**
Marie Chevret Measson, France

French language only

ML-02 MASTER LECTURE

16:30–17:00 **Auditorium 15**

Scandinavian Society for Sexual Medicine lecture: Pornography. What does it do for sexuality?

Chair: Annamaria Giraldi, Denmark
Speaker: Gert Martin Hald, Denmark

ML-03 MASTER LECTURE

17:00–17:30 **Auditorium 10/11**

History of ESSM

Chair: Jens Sønksen, Denmark
Speaker: Dimitris Hatzichristou, Greece

OPENING CEREMONY

17:30–18:30 **Auditorium 15**

- Welcome Speeches
- Announcement of ESSM 20th Anniversary

Scientific Program I Friday, 6 February 2015

LV-01 INDUSTRY SPONSORED LIVE SURGERY

08:30–12:00 **Auditorium 15**

see page 54

RT-05 ROUND TABLE

08:30–10:00 **Auditorium 10/11**

Paraphilias and BDSM in sexual medicine

Chairs: Francisco Santamaria Cabello, Spain
Giedre Jonusiene, Lithuania

001 **Paraphilias in DSM-V: A normal variation of sexual practices continuum?**
Per Briken, Germany

002 **The fifty shades of grey hype, is consent a grey area?**
Marijke Vonk, The Netherlands

003 **The psychosexual characteristics of BDSM practicioners**
Andreas Wismeijer, The Netherlands

004 **BDSM fantasies become practice**
Charlotta Calstrom, Sweden

WS-04 WORKSHOP

08:30–10:00 W **Auditorium 12**

Hormonal difficulties in men and women

Experts: Mario Maggi, Italy
Linda Vignozzi, Italy
Chair: Giovanni Corona, Italy

10:00–10:30 BREAK

HP-04 HIGHLIGHTED POSTER TOUR

10:00–10:30 **Hall A1**

Psychosexual issues and management

Chairs: Marieke Dewitte, Belgium
Paraskevi-Sofia Kirana, Greece

001 **Does compulsive sexual behavior really exist? Psychological, relational, and biological correlates of compulsive masturbation in a clinical setting**
Giovanni Castellini, Italy
G. Corona, E. Fanni, E. Maseroli, V. Ricca, M. Maggi

002 **Men with hypersexual disorder – an investigation of common characteristics**
Monika Emilsdottir, Denmark
C. Leffler, E. Grahn, A. Giraldi, E. Kristensen

003 **Recurrent prostatitis and sexuality**
Alessandro Franceschelli, Italy
E. V. Longhi, A. Salonia, G. Gentile, F. Colombo, F. Montorsi

004 **Psychosexual therapy: A ‚slow and strict' clinic in the heart of London**
Remziye Kunelaki, United Kingdom

005 **Sexuality as a topic in clinical practise amongst norwegian health personel**
Brynjar Landmark, Norway
B. Landmark, E. E. Pirelli Benestad, W. Fjeld, S. C. Kühle-Hansen, S. Schaller, B. Træen

006 **Sex without drugs versus sex with drugs: Sexual response, anxiety and attitudes**
Francisco Santamaria Cabello, Spain
F. J. Del Río Olvera, I. Fernández Agis, J. Strizzi

RT-06 INDUSTRY SPONSORED ROUND TABLE

10:30–12:00 **Auditorium 10/11**

see page 50

W Limited seats, pre-registration necessary/
Full description see page 42

WS-05 WORKSHOP

10:30–12:00 W **Auditorium 12**

Infertility and sexuality

Expert: Ates Kadioglu, Turkey
Chair: Natalio Cruz, Spain

001 **Male infertility and sexual dysfunction (prevalence, diagnosis, treatment)**
Natalio Cruz, Spain

002 **Female infertility and sexual dysfunction (prevalence, diagnosis, treatment)**
Johannes Bitzer, Switzerland

NS-04 NATIONAL SYMPOSIUM

10:30–12:30 **Room 18/19**

Joint AIUS/SFMS Symposium: New issues surrounding sexuality

Chairs: Mireille Bonierbale, France
Antoine Faix, France
Gilbert Bou Jaoude, France

001 **Introduction**
Mireille Bonierbale, France

002 **Tension in scripts on sexuality: "Hypersexual versus asexual"**
Alain Giami, France

003 **Group sex and sexological demand: Specific features of clinical pictures**
Beatrice Cuzin, France

004 **Sexual abstinence and unconsummated marriages: Assessment and care**
Pierre Martin Vauzour, France

005 **New sexuality for adolescents: From support to prevention of high-risk behaviours**
Marie Laure Gamet, France

006 **HIV and high-risk behaviours**
Gilbert Bou Jaoude, France

007 **Closing remarks**
Gilbert Bou Jaoude, France
Antoine Faix, France

English language only

ML-04 MASTER LECTURE

12:00–12:30 **Auditorium 10/11**

Award of Excellence

Chair: Linda Vignozzi, Italy
Speaker: Carla Costa, Portugal

12:30–14:00 BREAK

SA-02 INDUSTRY SPONSORED SYMPOSIUM

12:30–14:00 **Auditorium 15**

see page 54

RT-07 ROUND TABLE

14:00–15:30 **Auditorium 15**

The dual model in transgender care

Chairs: Cecilia Dhejne, Sweden
Guy T'Sjoen, Belgium

001 **Diagnostic issues and treatment of DSD**
John Dean, United Kingdom

002 **Approach of gender dysphoria in childhood and adolescence**
Peggy T. Cohen-Kettenis, The Netherlands

003 **Psychosocial care for DSD and transgender patients**
Timo O. Nieder, Germany

004 **Endocrinological aspects of transgender medicine**
Guy T'Sjoen, Belgium

RT-08 ROUND TABLE

14:00–15:30 **Auditorium 10/11**

Toys and vibratory devices for joy and medical need

Chairs: Arik Shechter, Israel
Luca Incrocci, The Netherlands

001 **The history of penile vibratory stimulation**
Jens Sønksen, Denmark

002 **Penile vibratory stimulation in ED treatment and penile rehabilitation**
Mikkel Fode, Denmark

003 **Sex toys: Use in sexual pleasure and dysfunction**
Yacov Reisman, The Netherlands

004 **The use of sexual surrogates in disabilities**
Woet L. Gianotten, The Netherlands

W Limited seats, pre-registration necessary/
Full description see page 43

Scientific Program I Friday, 6 February 2015

PS-04 PODIUM SESSION

14:00–15:30 **Auditorium 12**

Ejaculatory disorders, hormones and prostate diseases

Chairs: Abraham Morgentaler, USA
Mario Maggi, Italy

001 **Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: A comparative study**
Elisa Maseroli, Italy
G. Corona, F. Lotti, G. Rastrelli, E. Mannucci, G. Forti, M. Maggi

002 **Thyroid function, serum testosterone and prolactin don't seem to be risk factors in men complaining of premature ejaculation**
Mohamad Habous, Saudi Arabia
S. Mahmoud, O. Abdelwahab, W. Elhadek, M. Shamndy, Z. Abdelrahman, C. Nelson, J. Mulhall

003 **Clinical implications of measuring prolactin levels in males of infertile couples**
Francesco Lotti, Italy
G. Corona, E. Maseroli, M. Rossi, S. Degl´Innocenti, G. Rastrelli, G. Forti, M. Maggi

004 **Endogenous testosterone levels in erectile dysfunction males with arterial hypertension and target organ damage**
Konstantinos Konstantinidis, Greece
C. Vlachopoulos, N. Ioakeimidis, A. Aggelis, T. Pallantzas, Z. Kratiras, D. Terentes-Printzios, C. Fassoulakis, A. Rempelakos, D. Tousoulis

005 **Association between endogenous serum testosterone concentrations and aortic pressures and pulse wave amplification indices in erectile dysfunction patients**
Konstantinos Rokkas, Greece
C. Vlachopoulos, N. Ioakeimidis, A. Aggelis, D. Terentes-Printzios, M. Abdelrasoul, A. Samentzas, T. Askitis, D. Tousoulis

006 **Testosterone supplementation and sexual function: A meta-analysis study**
Giulia Rastrelli, Italy
G. Corona, A. Isidori, J. Buvat, A. Aversa, G. Hackett, V. Rochira, A. Sforza, A. Lenzi, E. Mannucci, M. Maggi

007 **Incidence of sexual dysfunction and effect of medical treatment for fertility on sexual functions in infertile men**
Selahittin Cayan, Turkey

008 **5-YR erectile function outcomes in patients submitted to either trans-urethral resection (TURP) or holmium laser enucleation of the prostate (HoLEP)**
Paolo Capogrosso, Italy
L. Boeri, A. Serino, E. Ventimiglia, G. La Croce, G. Castagna, A. Pecoraro, M. Paciotti, F. Montorsi, A. Salonia

009 **Combined treatment with Tradamixina® and Serenoa repens decreases PSA levels and prostate inflammation, improving the lower urinary tract symptoms (LUTS). A randomized, double-blind, placebo-controlled study on 185 patients**
Fabrizio Iacono, Italy
A. Ruffo, D. Prezioso, G. Romeo, E. Illiano, L. Romis, G. Di Lauro

010 **Metabolic syndrome and benign prostaticenlargement: A systematic reviewand meta-analysis**
Giovanni Corona, Italy
M. Gacci, L. Vignozzi, M. Salvi, S. Serni, C. De Nunzio, A. Tubaro, M. Oelke, M. Carini, M. Maggi

011 **A longitudinal analysis shows that symptoms of premature ejaculation are variable over time and causal of sexual distress**
Patrick Jern, Finland
M. Ristilä, A. Kärnä

012 **Sexual disorders in testicular cancer patients subjected to post-chemotherapy retroperitoneal lymph node dissection**
Konstantinos Dimitropoulos, Greece
A. Karatzas, I. Zachos, C. Papandreou, D. Daliani, L. Pisters, V. Tzortzis

013 **Sexual disorders for chronic bacterial prostatitis**
Khalid Ibishev, Russia
M. Kogan, A. Cherny, D. Krakhotkin

NS-05 NATIONAL SYMPOSIUM

14:00–15:30 **Room 18/19**

MESSM–Middle East Society for Sexual Medicine

001 **Sexuality in ancient Egypt**
Amr Elmeliegy, Egypt

002 **The effect of premature ejaculation in female sexual satisfaction**
Amr Gadalla, Egypt

003 **MESSM Public awareness website: The first of many landmarks to come**
Sandrine Atallah, Lebanon

English language only

15:30–16:00 BREAK

ML-05 MASTER LECTURE

15:30–16:00 **Auditorium 15**

Sex addiction: Moral myth or clinical reality?

Chair: Francesca Tripodi, Italy
Speaker: Paula Hall, United Kingdom

HP-05 HIGHLIGHTED POSTER TOUR

15:30–16:00 **Hall A1**

Peyronie's disease

Chairs: Wayne J. G. Hellstrom, USA
Beatrice Cuzin, France

001 **Lengthening albugineal graft-free z-plasty for Peyronie disease: Description of an original surgical technique and pilot study preliminary results**
Andrea Moiso, Italy
D. Rosso, P. Polledro

002 **Combined therapy using vacuum erection device and a nutraceutical compound (Tradamixina) in the early stages of Peyronie's disease**
Nikola Stanojevic, Serbia
V. Pesic, M. Tanasic, A. Ruffo

003 **The sliding technique for end stage Peyronie's disease with severe shortening of the penis: Surgical outcomes and patients satisfaction**
Massimiliano Timpano, Italy
C. Ceruti, O. Sedigh, D. Ralph, F. Colombo, C. Dadone, M. Falcone, F. Kuehhas, L. Rolle

004 **Plaque surgery with insertion of malleable penile prosthesis for severe Peyronies disease – real length improvement**
Evangelos Zacharakis, United Kingdom
M. Shabbir, G. Garaffa, F. Deluca, A. Raheem, D. J. Ralph

005 **Long-term outcomes of grafting procedure using autovein in patients with Peyronies disease**
Badri Gvasalia, Russia
B. Gvasalia, A. Kochetov, V. Parshin, R. Abramov, A. Borshevetskiy

006 **Functional evaluation after a surgery for penile curvature: A retrospective cohort study of 58 patients**
Arnaud Baldini, France
P. Paparel, A. Ruffion, N. Morel-Journel, N. Morel-Journel

007 **Penile prosthesis and albuginea incision is an easy and valuable option in Peyronies disease**
Carlo Luigi Augusto Negro, Italy
M. Paradiso, A. Rocca, F. Bardari

HP-06 HIGHLIGHTED POSTER TOUR

15:30–16:00 **Hall A1**

Surgical treatment of male sexual dysfunction

Chairs: Trygve Talseth, Norway
Trinity Bivalacqua, USA

001 **Penile implants act as a tissue expander and may lead to an increase in penile length and girth**
Amr Mohamed Abdel Raheem Mohamed, United Kingdom
F. De Luca, M. Spilitros, G. Garaffa, A. Muneer, S. Minhas, N. Christopher, D. Ralph, S. Larsen

002 **Our experience of penile augmentation with simultaneous penile implantation in patients with erectile dysfunction and penile dysmorphophoby**
Maksym Romaniuk, Ukraine
O. Kornyenko, I. Gorpynchenko, J. Gurzhenko, M. Lysenko

003 **No touch technique & Rifampicin reduce infection risk in penile prosthetic surgery**
Nabeel Kuwaijo, Ireland
P. Hegarty, H. Hegarty, N. Hegarty, K. O´Malley

004 **Anatomical study on ectopic placement of a cloverleaf reservoir in coloplast penile implants supported by the clinical outcome**
Daniar Osmonov, Germany
S. K. Wilson, C. M. Naumann, T. Wedel, J. Sievers, K. P. Juenemann

005 **Introducing the first registry for penile implants: The INSIST-ED REGISTRY (Italian Nationwide Inventarisation of Surgical Treatment for ED)**
Edoardo Pescatori, Italy
G. Franco

006 **Satisfaction after 2 pieces penile prosthesis implant: A multi-institutional Italian study**
Alessandro Franceschelli, Italy
G. Gentile, P. Massenio, A. Tuccio, S. Barbieri, L. Di Venuto, A. Natali, A. Vitarelli, L. Cormio, F. Colombo

Scientific Program I Friday, 6 February 2015

RT-16 INDUSTRY SPONSORED ROUND TABLE

16:00–17:15 **Auditorium 15**

see page 54

RT-09 ROUND TABLE

16:00–17:15 **Auditorium 10/11**

Is there a future for medical therapy of Peyronie's disease?

Chairs: Fulvio Colombo, Italy
Ilan Efraim Gruenwald, Israel

001 **Pathophysiology of Peyronie's disease: How can we easily identify new treatment targets?**
William Stebbeds, United Kingdom

002 **Mechanisms of penile fibrosis and the potential of NO/cGMP pathway modulation in Peyronie's disease**
Nestor Gonzalez-Cadavid, USA

003 **Oral therapy for Peyronie's disease: What we should prescribe and what we should not prescribe. That's the question!!**
Hartmut Porst, Germany

004 **Local and intralesional therapy for Peyronie's disease is a mainstay in the future**
Anthony J. Bella, Canada

RT-10 ROUND TABLE

16:00–17:15 **Auditorium 12**

Neurotransmitters, mood regulation and sexual behavior

Chairs: Kerstin Fugl-Meyer, Sweden
Marcel D. Waldinger, The Netherlands

001 **Neurotransmitters in female sexual function and dysfunction**
Tillmann Krüger, Germany

002 **Mood, psychotic disorders and sleep disorders – how do they affect sexuality?**
Michael Lew Starowicz, Poland

003 **Psychopharmacology and sexual function – good or bad?**
Annamaria Giraldi, Denmark

ESSM ANNUAL BUSINESS MEETING

17:30–18:30 **Auditorium 15**

– for members only –

1995 – 2015

VS-02 VIDEO SESSION

08:30–10:00 **Auditorium 15**

Complex reconstructive and plastic genital surgery

Chairs: Giulio Garaffa, United Kingdom
Nicolas Morel-Journel, France

001 **Ileal vaginoplasty: Tips, tricks and pitfalls**
Mark-Bram Bouman, The Netherlands

002 **Why do so many women think their vulva is abnormal and what can we correct? Composite reduction labiaplasty: Indications and technique**
Mujde Ozer, The Netherlands

003 **Penoplasty in the genetic male; tips, tricks and pitfalls**
Giulio Garaffa, United Kingdom

004 **Female genital mutilation, how to treat, how to reconstruct? (illustrated presentation)**
Beatrice Cuzin, France

005 **Complex genitalia reconstruction for acute and rare case of penile pyoderma gangrenosum**
Omid Sedigh, Italy

006 **Reconstruction of penile injuries**
Miroslav Djordjevic, Serbia

PS-08 PODIUM SESSION

08:30–09:00 **Auditorium 12**

Late breaking abstracts in basic and clinical male sexual dysfunction research

Chairs: Paolo Capogrosso, Italy
Selim Cellek, United Kingdom

001 **Low-energy linear extracorporeal shock wave therapy for erectile dysfunction**
Grzegorz Fojecki, Denmark
S. Tiessen, P. Osther

002 **Does still is a place for paroxetine in the era of dapoxetine**
Aleksander Khelaia, Georgian

003 **Although nitrergic function is profoundly impaired, the endothelial function is preserved in the corpus cavernosum and penile resistance arteries of men after radical prostatectomy**
Juan Ignacio Martinez-Salamanca, Spain
J. M. La Fuente, A. Fernández, E. Martínez-Salamanca, A. J. Pepe-Cardoso, J. Carballido, J. Angulo

RT-11 ROUND TABLE

08:30–10:00 **Auditorium 10/11**

Testosterone substitution and male sexual health

Chairs: Eduardo Garcia-Cruz, Spain
Zdravko Asenov Kamenov, Bulgaria

001 **Testosterone and sexual function, what's the physiological connection?**
Stefan Arver, Sweden

002 **PRO: Clinical evidence (male sexual health)**
Mario Maggi, Italy

003 **CON: Clinical evidence (male sexual health)**
Geoffrey Hackett, United Kingdom

004 **Does T supplementation increase PDE5-inhibitor responses in difficult-to-treat ED patients?**
Antonio Aversa, Italy

NS-06 NATIONAL SYMPOSIUM

08:30–12:30 **Room 18/19**

ASESA– Associación Española de Andrología/SPA–Sociedad Portuguesa de Andrologia

Chairs: Pepe Cardoso, Portugal
Rafael Prieto, Spain

Sindrome post-finasteride: Realidad o ficcion
Eduardo Garcia-Cruz, Spain

Manejo de la eyaculacion retardada
Bruno Pereira, Portugal

Vasectomia

Chairs: Pepe Cardoso, Portugal
Ana María Puigvert Martínez, Spain

Tecnica quirurgica
Jose Viladoms, Spain

Manejo de las complicaciones
Ignacio Sola, Spain

Reversion
Vitor Oliveira, Portugal

Deficit de testosterona: Novedades en 2015
Nuno Louro, Portugal

Disfuncion érectil: Novedades en 2015
Asier Leibar, Spain

Enfermedad de Peyronie: Novedades en 2015
Joaquin Sarquella, Spain

Spanish language only

Scientific Program I Saturday, 7 February 2015

Cirugia protésica

Chairs: Pedro Vendeira, Portugal
Natalio Cruz, Spain

Manejo de la infeccion
Javier Romero Otero, Spain

Implante doble: EUA o Sling
Augustin Fraile, Spain

Mejorar la satisfactión
Nuno Tomada, Portugal

Rehabilitacion vs tratamiento de la DE tras prostatectomia radical
Juan Ignacio Martinez-Salamanca, Spain

WS-06 **WORKSHOP**

09:00–10:00 W **Auditorium 12**

Vulvodynia, vestibulodynia and sexual pain disorders (diagnosis, examination and treatment)

Expert: Johannes Bitzer, Switzerland
Chair: Lior Lowenstein, Israel

10:00–10:30 BREAK

HP-07 **HIGHLIGHTED POSTER TOUR**

10:00–10:30 **Hall A1**

Ejaculatory disorders

Chairs: Marcel D. Waldinger, The Netherlands
Emmanuele A. Jannini, Italy

001 **Current smoking is associated with lower seminal vesicles and ejaculate volume, despite higher testosterone levels, in male subjects of infertile couples**
Francesco Lotti, Italy
G. Corona, P. Vitale, E. Maseroli, M. Rossi, M. G. Fino, M. Maggi

003 **Voiding phase luts negatively impacts ejaculatory function – results of a psychometric study in men seeking medical attention for premature ejaculation**
Eugenio Ventimiglia, Italy
P. Capogrosso, A. Serino, L. Boeri, G. La Croce, G. Castagna, A. Pecoraro, M. Paciotti, R. Scano, F. Montorsi, A. Salonia

004 **Characteristics of patients attending sex-therapist physicians for premature ejaculation in France**
Marie Helene Colson, France
S. Droupy, P. Maigret, P. Costa

005 **Blood prostate specific antigen can predict erectil and ejaculation dysfunction**
Göksel Bayar, Turkey
M. Aydin, M. Kendirci

006 **Pelvic floor muscle rehabilitation for patients with lifelong premature ejaculation: A novel therapeutic approach**
Antonio Luigi Pastore, Italy
G. Palleschi, L. Silvestri, A. Fuschi, C. Maggioni, A. Carbone

007 **Presentation and treatment outcome of ejaculatory duct obstruction (EDO)**
Amr Mohamed Abdel Raheem Mohamed, United Kingdom
F. De Luca, M. Spilitros, G. Garaffa, S. Minhas, N. Christopher, A. Muneer, D. Ralph, C. Ying-Li

HP-08 **HIGHLIGHTED POSTER TOUR**

10:00–10:30 **Hall A1**

Risk factors and medical management I

Chairs: Paolo Verze, Italy
Hans Joergen Kirkeby, Denmark

001 **Early effect of bariatric surgery on urogenital function in morbidly obese male patients: Preliminary observations**
Maha Aleid, United Kingdom
S. Cellek, A. Muneer, M. Hashemi, J. George, S. Renshaw

002 **One out of ten patients submitted to radical prostatectomy complains of postoperative painful orgasm**
Paolo Capogrosso, Italy
A. Serino, E. Ventimiglia, L. Boeri, G. La Croce, A. Pecoraro, M. Paciotti, G. Gandaglia, A. Briganti, F. Montorsi, A. Salonia, A. Serino

003 **Tailoring to the patient with erectile dysfunction – baseline clinical characteristics are of major importance to predict positive treatment outcomes**
Paolo Capogrosso, Italy
E. Ventimiglia, A. Serino, L. Boeri, G. La Croce, M. Paciotti, R. Scano, R. Damiano, F. Montorsi, A. Salonia

004 **The recovery of sexual function in patients with vasculogenic erectile dysfunction**
Maksym Romaniuk, Ukraine

005 **New treatment for erectile dysfunction using a nutraceutical compound (Tradamixina®). A randomized, double-blinded, placebo controlled study on 92 patients**
Nikola Stanojevic, Serbia
V. Pesic, M. Tanasic

W Limited seats, pre-registration necessary/
Full description see page 44

006 **Statin treatment in erectile dysfunction patients with obesity and hypercholesterolemia**
Inês Tomada, Portugal
N. Tomada

007 **Evaluation of radial extracorporeal shock wave therapy in the treatment of erectile dysfunction**
Pavel Pokorny, Czech Republic
P. Turcan, P. Pokorny, M. Prochazka, J. Prochazkova

008 **Hypogonadal men with pre-existing cardiovascular disease (CVD) show improved erectile function on long-term treatment with testosterone undecanoate injections**
Farid Saad, Germany
G. Doros, A. Haider, A. Traish

HP-09 HIGHLIGHTED POSTER TOUR

10:00–10:30 **Hall A1**

Hormones and male sexual health

Chairs: Ilpo Huhtaneimi, Finland
Mats Holmberg, Sweden

001 **Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events**
Elisa Maseroli, Italy
G. Corona, G. Rastrelli, A. Sforza, G. Forti, E. Mannucci, M. Maggi, N. Fralassi

002 **Low testosterone and high pulse pressure are complementary predictors of cardiovascular events in erectile dysfunction patients**
Nikolaos Ioakeimidis, Greece
C. Vlachopoulos, K. Rokkas, A. Aggelis, M. Abdelrasoul, Z. Kratiras, C. Fassoulakis, A. Rempelakos, D. Tousoulis

003 **Erectile dysfunction correlates with MetS in men with moderate prostatic symptoms**
Eduard García Cruz, Spain
J. I. Martínez-Salamanca, J. Romero Otero

004 **Gynecomastia in subjects with sexual dysfunction**
Elisa Maseroli, Italy
G. Rastrelli, G. Corona, V. Boddi, A. M. Letizia Amato, E. Mannucci, G. Forti, M. Maggi

005 **Erectile dysfunction and aging symptoms are related to a higher Charlson Comorbidity Index**
Eduard García Cruz, Spain
J. I. Martínez-Salamanca, R. Javier

006 **Temporary withdrawal of testosterone treatment in morbidly obese hypogonadal men a series of case reports**
Farid Saad, Germany
A. Yassin, A. Traish

007 **Testosterone level predicts outcome of phosphodiesterase-5 inhibitor treatment**
Christopher Ho, Malaysia
A. Akhavanmalyeri, M. H. Jasman, G. H. Tan, P. Singam, E. H. Goh, B. Bahadzor, Z. Zainuddin

ML-06 MASTER LECTURE

10:30–11:00 **Auditorium 15**

ESSM: Two decades of research in sexual medicine – what has been translated from basic science to the patient?

Chair: Javier Angulo, Spain
Speaker: Petter Hedlund, Sweden

WS-07 WORKSHOP

11:00–12:00 **W** **Auditorium 12**

How to improve patient satisfaction and compliance

Expert: John Dean, United Kingdom
Chair: Paraskevi-Sofia Kirana, Greece

RT-12 ROUND TABLE

11:00–12:30 **Auditorium 15**

Are male factor infertility and male sexual dysfunction linked?

Chairs: Jens Sønksen, Denmark
Dana Ohl, USA

001 **Environmental factors: A shared etiological factor in infertility and sexual dysfunction?**
Raanan Tal, Israel

002 **Psychological impact of male factor infertility and the influence on masculinity and male sexual function**
Zsolt Kopa, Hungary

003 **Effects of infertility and infertility treatment on male sexual function**
Francesco Lotti, Italy

004 **Benefits and risks of hormonal treatment in infertile males**
Selahittin Cayan, Turkey

W Limited seats, pre-registration necessary/
Full description see page 44

Scientific Program I Saturday, 7 February 2015

PS-05 PODIUM SESSION

11:00–12:30 **Auditorium 10/11**

Sexual diversity and gender dysphoria

Chairs: Esben Esther Pirelli Benestad, Norway
Timo O. Nieder, Germany

001 **Body uneasiness and eating disorders symptoms in gender dysphoria individuals**
Alessandra Daphne Fisher, Italy
G. Castellini, H. Casale, E. Fanni, I. Lasagni, L. Benni, V. Ricca, M. Maggi

002 **Time needed for cross-sex hormonal treatment to induce physical changes as well as to improve gender dysphoria in MtF individuals**
Alessandra Daphne Fisher, Italy
G. Castellini, E. Fanni, H. Casale, A. Amato, V. Boddi, E. Maseroli, C. Meriggiola, V. Ricca, M. Maggi

003 **A network approach to body satisfaction in gender dysphoria**
Tim van de Grift, The Netherlands
P. Cohen-Kettenis, G. DeCuypere, H. Richter-Appelt, I. Haraldsen, B. Kreukels

004 **The gay men sex studies: Prevalence of infidelity and promiscuity among Belgian gay men**
Johan Vansintejan, Belgium
J. Vandevoorde, D. Devroey

005 **Endoscopic characteristics of the sigmoid-derived neovagina**
Wouter van der Sluis, The Netherlands
J. Meijerink, L. Elfering, M. Mullender, N. de Boer, A. van Bodegraven, M.-B. Bouman

006 **Psychosocial outcome and quality of sexual life after sex reassignment surgery: An Italian multicentric study**
Antonio Prunas, Italy
D. Hartmann, M. Bini, E. Bandini, A. Fisher, M. Maggi, V. Pace, O. Todarello, L. Quagliarella

007 **An exploration of transgender identity through the Implicit Association Test (IAT)**
Antonio Prunas, Italy
M. Bini, D. Hartmann

008 **The global online sexuality survey (GOSS): Male homosexuality among Arabic-speaking internet users in the Middle East – 2010**
Osama Shaeer, Egypt

009 **Is homosexuality viewed as a disease? The picture from a real-life sociological assessment**
Luca Boeri, Italy
A. Serino, G. La Croce, E. Ventimiglia, I. Camozzi, M. Salonia, A. Pecoraro, M. Paciotti, R. Damiano, F. Montorsi, A. Salonia

010 **On hypersexual disorder-psychiatric co-morbidities, paraphilias and gender differences in women and men with self-identified hypersexual behavior**
Katarina Görts Öberg, Sweden
J. Hallberg, C. Dhejne, S. Arver

PS-09 PODIUM SESSION

12:00–12:30 **Auditorium 12**

Late breaking abstracts in female sexual dysfunction and psychosexual research

Chairs: Arik Shechter, Israel
Cecilia Dhejne, Sweden

001 **Sexual patterns in drug-addicted women**
Stefania Chiappini, Italy
T. Roberta, M. Di Paolo, G. Conte

002 **Gender-related differences in the associations between sexual impulsivity and psychiatric disorders**
Galit Erez, Israel
C. Pilver, M. Potenza

003 **Relationship between desire, sexual attitudes and menstruation**
Francisco Santamaria Cabello, Spain
F. J. Del Río Olvera, M. A. Cabello-García

12:30–13:30 BREAK

RT-13 ROUND TABLE

13:30–15:00 **Auditorium 15**

Debate: Testosterone supplementation: Safe for the heart?

Chairs: Michael Zitzmann, Germany
Pedro Vendeira, Portugal

001 **PRO: Testosterone administration is safe for the heart**
Abraham Morgentaler, USA

002 **CON: Testosterone supplementation: Increased risk for cardiovascular events: What the data tells us**
Ilpo Huhtaniemi, Finland

Interactive discussion

PS-06 PODIUM SESSION

13:30–15:00 **Auditorium 10/11**

Female sexual dysfunction

Chairs: Johannes Bitzer, Switzerland
Birgitta Hulter, Sweden

001 **The prevalence and predictors of female sexual dysfunction: A systematic review and meta-analysis**
Megan McCool, Germany
A. Zuelke, M. Theurich, C. Apfelbacher

002 **Help seeking behavior for female sexual dysfunction among middle aged Egyptian women**
Doaa Elkowessny, Germany
M. Abu-Nazel, S. Ghobashy, H. Salama

003 **Female sexual dysfunction may be associated with low sleep quality in patients with fibromyalgia**
Akin Soner Amasyali, Turkey
E. Tastaban, S. Y. Amasyali, Y. Turan, E. Kazan, I. Kocak, H. Erol

004 **Oral sex in Indonesia: Trend and threat**
I Putu Yuda Hananta, Indonesia

005 **Hymen protection between sexual euphoria and cultural dysphoria**
Faysal El Kak, Lebanon
R. Yasmine, N. El Salibi, L. Ghandour

006 **Sexual functioning in couples where female partner has endometriosis**
Natalia Stenyaeva, Russia
N. Stenyaeva, D. Chritinin, G. Suchich

007 **Confirmatory validation of a fear avoidance model of Vaginismus in a sample of Iranian women**
Mitra Molaei Nezhad, Islamic Republic of Iran
A. Yousefy, M. Salehi, Z. Dehghani, P. Salehi, E. Merghati Khoei, R. Latifnejad Roudsari

008 **Six out of ten women seeking medical help for recurrent urinary tract infections suffer from distressful sexual function impairment – a worrisome picture from the real-life setting**
Luca Boeri, Italy
A. Pecoraro, M. Paciotti, E. Ventimiglia, P. Capogrosso, A. Serino, G. Castagna, R. Scano, R. Damiano, F. Montorsi, A. Salonia

009 **Effect of chronic intransasal oxytocin on female sexual function in pre- and postmenopausal women**
Michaela Bayerle-Eder, Austria
D. Muin, S. Sheikh Rezaei, M. Wolzt, R. Marculescu, E. Bragagna, M. Salama, C. Fuchs, B. Litschauer, A. Luger

010 **A comprehensive evaluation of masturbation characteristics and preferences in a sample of Italian women**
Gaia Polloni, Italy
S. Di Santo, A. Prunas, G. Mori, R. Bernorio

011 **Treatment of female sexual dysfunction improves sexual quality of life and depression in male partners**
Dana Anais Muin, Austria
S. Sheikh Rezaei, M. Wolzt, M. Salama, A. Luger, M. Bayerle-Eder

012 **Physician attitudes towards androgen replacement therapy for sexual dysfunction in both genders**
Lior Lowenstein, Israel
A. Shechter, F. Tripodi, H. Porst, Y. Reisman

013 **Is there a correlation between androgens and sexual desire in women?**
Sarah Wåhlin-Jacobsen, Denmark
A. T. Pedersen, E. Kristensen, N. C. Læssøe, M. Lundqvist, A. Cohen, D. M. Hougaard, A. Giraldi

014 **The doctor's perception on sexual history taking in adolescent females attending the accident and emergency department with abdominal pain**
Cassie McDonald, United Kingdom
K. Orf, L. Stroman

015 **Pelvic/genital pain in women with psychiatric disorders**
Goran Arbanas, Croatia
E. Ivezic, S. Maroevic, I. Jerkovic

PS-07 PODIUM SESSION

13:30–15:00 **Auditorium 12**

Basic science and translational research

Chairs: Nestor Gonzales-Cadavid, USA
Carla Costa, Portugal

001 **Increased levels of TNF-alpha following bilateral cavernous nerve injury leads to neurite-outgrowth impairments from major pelvic ganglion**
Trinity Bivalacqua, USA
H. Matsui, J. L. Hannan, X. Liu, M. Albersen

002 **The neurotrophic peptide galanin stimulates neurite growth of pelvic neurons**
Emmanuel Weyne, Belgium
J. L Hannan, X. Lu, F. Castiglione, D. de Ridder, F. Van der Aa, T. J Bivalacqua, M. Albersen

Scientific Program I Saturday, 7 February 2015

003 **Vasculogenesis and diabetic erectile dysfunction: How relevant is glycemic control?**
Angela Castela, Portugal
P. Gomes, R. Silvestre, L. Guardão, L. Leite, P. Vendeira, C. Costa

004 **Tadalafil ameliorates MetS-induced alterations by inducing a „Brown-like" phenotype in visceral adipose tissue: An experimental study in the rabbit**
Linda Vignozzi, Italy
I. Cellai, A. Aversa, T. Mello, S. Filippi, P. Comeglio, D. Bani, A. Morelli, M. Maggi

005 **Development of a high-throughput, cell-based assay for anti-myofibroblast activity in Peyronie's disease**
William Stebbeds, United Kingdom
M. Mateus, B. Ameyaw, A. Raheem, M. Spilotros, G. Garaffa, A. Muneer, N. Christopher, S. Cellek, D. Ralph

006 **Stimulation of calcium-activated potassium channels (KCa) as a strategy to modulate enhanced neurogenic contractions of corpus cavernosum**
Javier Angulo, Spain
J. I. Martínez-Salamanca, J. M. La Fuente, A. Fernández, E. Martínez-Salamanca, A. J. Pepe-Cardoso, J. Carballido

007 **Synergistic effects of Y-27632 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure**
Pieter Uvin, Belgium
M. Albersen, I. Bollen, M. Falter, L. Linsen, H. Tinel, P. Sandner, T. Bivalacqua, D. de Ridder, F. van der Aa, B. Brône, K. van Renterghem

008 **Role of SK3 channes in erectile function in mice**
Simon Comerma Steffensen, Denmark
A. Kun, E. Hedegaard, B. Mønster Christensen, S. Mogensen, C. Aalkjaer, R. Kohler, U. Simonsen

009 **Influence of vardenafil on sperm hyperactivation**
Fotios Dimitriadis, Greece
P. Tsounapi, S. Skouros, S. Stavrou, S. Tomita, A. Takenaka, N. Sofikitis

010 **The beneficial effect of intracavernosal fesoterodine (competitive muscarinic receptor antagonist) on erectile dysfunction of diabetic rats**
Serap Gur, Turkey
D. Yilmaz, E. Kaya, D. Yilmaz

011 **Antioxidant therapy with alga ecklonia bicyclis, tribulus terrestris, glucosamine oligosaccharide and myo-inositol reduces oxidative stress, lipid peroxidation and DNA-fragmentation in men with oligoasthenozoospermia**
Fabrizio Iacono, Italy
A. Ruffo, D. Prezioso, G. Romeo, E. Illiano, L. Romis, G. Di Lauro

012 **Tadalafil restores penile neuronal nitric oxide synthase levels which decreases with chronic paroxetine treatment**
Ege Can Serefoglu, Turkey
A. Gul, L. Kabasakal, D. S. Celik, A. Semercioz

013 **Nerves and vessels in the corpora cavernosa and corpus spongiosum. Analysis of their development in the human penis during the whole fetal period**
Carla Gallo, Brazil
W. Costa, B. Gregorio, F. Sampaio

NS-07 **NATIONAL SYMPOSIUM**

13:30–16:15 **Room 18/19**

Scandinavian Society for Sexual Medicine: Sexual function in cancer patients and SSSM General Assembly

001 **Introduction and status of the Congress and the SSSM**
Mikkel Fode, Denmark

002 **Genital cancer, male identity and couples' sexual satisfaction**
Luca Incrocci, The Netherlands

003 **Sexual function in androgen deprivation therapy**
Peter Østergren, Denmark

004 **Cancer and female sexual dysfunction**
Gideon Sartorius, Switzerland

English language only
SSSM General Assembly (in Scandinavian language)

ML-07 **MASTER LECTURE**

15:00–15:30 **Auditorium 15**

What happened to good old Masters & Johnson? An update on pharmacological and non-pharmacological PE treatment in 2015
Chair: Ege Can Serefoglu, Turkey
Speaker: Chris G. McMahon, Australia

15:30–16:00 BREAK

HP-10 HIGHLIGHTED POSTER TOUR

15:30–16:00 **Hall A1**

ED risk factors and medical management II

Chairs: Juan Ignacio Martinez-Salamanca, Spain
Ferdinando Fusco, Italy

001 **The expression of adenosine receptors in Peyronie's Disease**
Marta Mateus, United Kingdom
W. Stebbeds, A. Raheem, M. Spilotros, G. Garaffa, A. Muneer, N. Christopher, S. Cellek, D. Ralph

002 **Penile linear shock wave therapy for poor responders to prior erectile dysfunction therapy**
Vipan Bhatia, United Arab Emirates

004 **Why do patients prefer daily over on demand tadalafil for erectile dysfunction**
Vipan Bhatia, United Arab Emirates

005 **The interaction between male sexual function and female sexual satisfaction in patient treated with a combined therapy for erectile dysfunction**
Valentina Boddi, Italy
H. Casale, G. Rastrelli, A. D. Fisher, M. Maggi

006 **Low-energy shock wave therapy–a new treatment for erectile dysfunction**
Maksym Romaniuk, Ukraine
P. Aksonov, I. Gorpynchenko

007 **Sexual techniques in long term catheterised males by "Innovative couples" – amazing but true**
Sanjay Pandey, India

HP-11 HIGHLIGHTED POSTER TOUR

15:30–16:00 **Hall A1**

Prostatic disease and male sexual health

Chairs: Giorgio Bozzini, Italy
Lars Lund, Denmark

001 **Prospective evaluation of the early impact of the LHRH analogues in the treatment of prostate cancer in sexual, psycho-cognitive, emotional and quality of life parameters**
Lucía García González, Spain
J. Romero Otero, R. Sopeña Sutil, E. Jiménez Alcaide, B. García Gómez, J. M. Duarte Ojeda, A. Rodríguez Antolín, J. Romero Otero

002 **Nocturia has a detrimental impact on sexual function – findings from a real-life survey in a cohort of Caucasian-European men**
Luca Boeri, Italy
G. Castagna, P. Capogrosso, E. Ventimiglia, A. Serino, A. Pecoraro, M. Paciotti, R. Scano, F. Montorsi, A. Salonia

003 **Relationship between extraplevic risk factors and lower urinary tract symptoms on older fourty years age men**
Göksel Bayar, Turkey
M. Ötüken, M. Aydin, M. Kendirci

004 **Combination therapy with triomen quattro and meloxicam in the treatment of lower urinary tract symptoms (LUTS) and prostate pain syndrome (PPS)**
Aleksander Khelaia, Georgian
L. Managadze

005 **Sexual activity and erectile function in men undergoing androgen deprivation therapy**
Peter Østergren, Denmark
C. Kistorp, J. Sønksen, M. Fode

006 **Erectile rehabilitation by sildenafil post radical prostatectomy and radical cystectomy. A prospective randomized study**
Mohamed Mourad Gargouri, Tunisia
Y. Ouanes, A. Sellami, Y. Ayari, Y. Nouira

007 **Evaluation of erectile dysfunction management in primary care**
Simon Morton, United Kingdom
C. Jones, M. Fraser

RT-14 ROUND TABLE

16:00–17:30 **Auditorium 15**

Incontinence and FSD

Chairs: Yoram Vardi, Israel
Juan M. Poyato Galan, Spain

001 **Menopause and its impact on the pelvic floor: Sexual dysfunction, prolaps and incontinence**
Rossella E. Nappi, Italy

002 **The link between urge urinary incontinence and sexual function and dysfunction in women**
Ian Milsom, Sweden

003 **The impact of pelvic floor surgery on female sexual function**
Milou Bekker, The Netherlands

004 **Pelvic floor physical therapy in FSD and urinary incontinence**
Anna Willans, United Kingdom

Scientific Program I Saturday, 7 February 2015

RT-15 **ROUND TABLE**

16:00–17:45 **Auditorium 10/11**

Panel discussion: Sexual side-effects of BPH treatment: Practical implications and prevention

Chairs: Ferdinando Fusco, Italy
Hartmut Porst, Germany

001 **Microvascular dysfunction as a common aetiology in ED and male LUTS**
Selim Cellek, United Kingdom

002 **Medical treatment for BPH: PDE5-inhibitors**
Matthias Oelke, Germany

003 **Medical treatment for BPH: Alpha blockers**
Wayne J. G. Hellstrom, USA

004 **Medical treatment for BPH: 5-alpha reductase inhibitors**
Onder Yaman, Turkey

005 **Minimal invasive endoscopic management of BPH: Does it impact sexual function?**
Christian Gratzke, Germany

006 **Can we prevent retrograde ejaculation during endoscopic resection and evaporation of the prostate and bladder neck?**
Saladin Alloussi, Germany

CLOSING CEREMONY

17:45–18:00 **Auditorium 10/11**

- Best Presentation Awards
- Congress Announcement 2016

Visit the Poster Exhibition in Hall A1

Opening Hours

Thursday, 5 February 2015	10:00 – 20:00
Friday, 6 February 2015	08:30 – 17:00
Saturday, 7 February 2015	08:30 – 17:00

Poster Presentations

P-01 MALE SEXUAL DYSFUNCTION

001 **Periurethral injection of human adipose tissue derived stem cells (hADSCs) prevents fibrosis in a new rat model of urethral stricture**
Fabio Castiglione, Italy
D. De Ridder, M. Albersen, S. Joniau, T. Bivalacqua, A. Russo, F. Benigni, F. Montorsi, P. Hedlund

002 **Sexual arousal and sexual inhibition: Qualitative study on italian men through focus group**
Davide Pappalardo, Italy
M. Panzeri

003 **Attitudes, self-esteem and sexual dysfunctions: Prevalence and clinical features in a group of young adult male**
Jacopo Grisolaghi, Italy
R. S. Calabrò

004 **Use of erectile dysfunction as a tool for early diagnosis of cardiovascular diseases**
Oleg Apolikhin, Russia
E. Efremov, S. Krasnyak

005 **Penil severity scale can use to predict penil shortening**
Göksel Bayar, Turkey
M. Aydin, M. Kadihasanoglu, M. Kendirci

006 **Evaluation of endothelial function by peripheral arterial tonometry in patients with erectile dysfunction**
Rui Duarte Abreu, Portugal

007 **The correlation between 25-OH-vitamin D and erectile dysfunction (ED)**
Ion Dumbraveanu, Republic of Moldova
V. Ghenciu, B. Balutel

008 **Modifiable risk factors for cardiovascular disease and erectile dysfunction – an analysis of the patients knowledge in men with ischaemic heart disease**
Dariusz Kalka, Poland
L. Karpinski, Z. Domagala, J. Gebala, W. Bek, L. Rusiecki, A. Grychowski, K. Jacyna, M. Rusiecka, W. Pilecki

009 **The analysis of the influence of the presence of modifiable risk factors for cardiovascular disease on the cardiologistis´ interest in erectile dysfunction in patients with ischaemic heart disease**
Dariusz Kalka, Poland
Z. Domagala, L. Karpinski, J. Gebala, L. Rusiecki, A. Bielous-Wilk, E. Sylwina-Krauz, J. Dworak, W. Beck, W. Pilecki

010 **An integral approach when facing age-related health problems in men: What should we focus on?**
Antonio Martin-Morales, Spain
R. Vozmediano Chicharro, V. Baena Gonzalez

011 **Objectification and sexual dysfunctions in men**
Antonio Prunas, Italy
A. Dakanalis, R. Bernorio, G. Mori

012 **A protocol of duplex ultrasound after cavernous injection of alprostadil**
Pablo Velilla, Spain
A. Puerta, D. Garcia-Escudero, P. Samper, A. Vilchez, J. P. Morga, J. Oñate, M. Torres, L.O. Fontana

013 **Healthy diet versus smoking impact on erectile dysfunction patient's heart geometry and diastolic performance; the good the bad and the final countdown**
Konstantinos Konstantinidis, Greece
A. Angelis, N. Ioakimidis, K. Makarounis, K. Rokkas, P. Vrettas, M. Abdelrasoul, C. Fasoulakis, C. Vlachopoulos, D. Tousoulis

014 **Vascular, cardiac and erectile dysfunction; the dangerous triad of atherosclerosis and the holistic contribution of the Mediterranean diet in the maintenance of cardiovascular health**
Konstantinos Rokkas, Greece
C. Vlachopoulos, A. Angelis, N. Ioakimidis, Z. Kratiras, P. Vrettas, F. Monpaient, K. Aggeli, K. Konstantinidis, D. Tousoulis

015 **Additional tadalafil therapy in tamsulosin non-responders with LUTS/BPH**
Vipan Bhatia, United Arab Emirates

016 **Drug treatment for ED and PE patients**
Bin Chen, China
T. Zhang, H. Wang, R. Chen, Y. Han, Y. Huang, Y. Huang

017 **Injectable testosterone undecanoate for the treatment of hypogonadism**
Elisa Maseroli, Italy
G. Corona, M. Maggi

018 **Determining factors of the regenerative capacity of the stromal vascular fraction**
Marlene Quaade, Denmark
C. H. Jensen, D. C. Andersen, S. P. Sheikh

019 **Improvement and stabilization of erectile function, anthropometric and metabolic parameters in hypogonadal men with type 2 diabetes mellitus (T2DM) on long-term treatment with testosterone undecanoate injections**
Farid Saad, Germany
G. Doros, A. Haider, A. Traish

Poster Presentations

020 **Multiple treatment modifications are independent of time since first prescription of a PDE5i results of real-life observational study**
Alessandro Serino, Italy
L. Boeri, P. Capogrosso, G. La Croce, E. Ventimiglia, A. Pecoraro, M. Paciotti, G. Castagna, R. Damiano, F. Montorsi, A. Salonia

021 **Three-pieces inflatable penile prosthesis implantation with penoscrotal approach and scrotal septum sparing technique: Description and early experience**
Enrico Conti, Italy
F. Varvello, S. Lacquaniti, M. Camilli, J. Antolini, G. Fasolis

022 **Venous leakage treatment revisited – pelvic veno-ablation using aethoxysclerol under air block technique and valsalva maneuver**
Ralf Herwig, Austria
S. Sansalone

024 **Penile implants; new pump system: 100 cases, our experience**
Mariano Rosselló, Spain
P. Garcia Abad, M. Fernandez Arjona

025 **Protective effects of oral supplementation with L-glutamine on irradiated prostate of rats**
Flavia Morone, Brazil
C. Gallo, F. Sampaio, D. Benchimol, W. Costa

026 **Critical evaluation of Peyronie´s disease (PD) treatment with plaque excision and grafting of the tunical defect with lyophilized bovine pericardium**
Borja Garcia Gomez, Spain
J. Romero Otero, J. Medina Polo, L. Garcia Gonzalez, E. Jimenez Alcaide, A. Rodriguez Antolin, J. Passas Martinez

027 **Superficial tunica albiginea rupture as initial startpoint of Peyrone's disease a topic for interdisciplinary consideration**
Ralf Herwig, Austria
M. Bayerl

028 **Post-surgical management of Peyronie's disease. How to prevent erectile dysfunction, penile shortening and curvature recurrence combining cacuum erection device therapy and Tradamixina®**
Nikola Stanojevic, Serbia
V. Pesic, M. Tanasic

029 **Hormone levels and Peyronie's disease: More than testosterone deficiency?**
Mariana Santiago, Portugal
F. Botelho, I. Tomada

030 **What bothers men about Peyronie's?**
Ross Vint, United Kingdom
A. Gibson, M. Fraser

031 **The nesbit procedure for Peyronie's disease: Six year follow up**
Tet Yap, United Kingdom
A. Raheem, M. Spilotros, F. De Luca, G. Garaffa, N. Christopher, S. Minhas, D. Ralph

032 **Our experience in penile fracture management**
Mohamed Mourad Gargouri, Tunisia
Y. Ayari, A. Sellami, M. A. Ben Chehida, S. Ben Rhouma, Y. Nouira

033 **Organ sparing surgery in penile cancer – our initial experience**
Sofia Lopes, Portugal
A. Silva, A. Furtado, M. Lourenço, P. Cardoso

034 **Glansectomy and partial penectomy for penile cancer under local anaesthesia**
Shafiullah Wardak, United Kingdom
J. Rai, N. Anastasius, D. Summerton, J. Goddard

035 **Surgical techniques and outcomes for squamous cell carcinoma of the urethra**
Tet Yap, United Kingdom
I. Cullen, N. Christopher, G. Garaffa, D. Ralph, S. Minhas

036 **Reduction of enlarged labia minora as a functional and aesthetic procedure**
Marta Bizic, Serbia
M. Djordjevic, V. Kojovic, M. Majstorovic, B. Stojanovic

037 **Consideration of female genital surgery and its correlates**
Verena Klein, Germany

038 **Treatment of gland and penile reconstructive/estetic surgery whit polyacrylamide gel**
Mauricio Salas Sironvalle, Chile
A. Salas Vieyra

039 **Sexual outcomes after partial penectomy for penile cancer: Results from a multiinstitutional study**
Salvatore Sansalone, Italy
M. Silvani, R. Leonardi, G. Vespasiani, V. Iacovelli

040 **Penile fractures in a tertiary UK referral centre – the functional outcome**
Evangelos Zacharakis, United Kingdom
M. Shabbir, A. Raheem, G. Garaffa, N. Christopher, A. Muneer, D. Ralph

Poster Presentations

041 **Impact of treatments for lower urinary tract symptoms/benign prostatic hyperplasia on ejaculation**
Kim Drasa, Albania
E. Dani

042 **Does still is a place for paroxetine in the era of dapoxetine**
Aleksander Khelaia, Georgian
L. Managadze, Z. Marshania

043 **Hemiscrotal orgasmic pain treated by phosphodiesterase 5 inhibition**
Nabeel Kuwaijo, Ireland
P. Hegarty, H. Hegarty, N. Hegarty, K. O´Malley

044 **Anejaculatory orgasm: Dilemmas in management**
Sanjay Pandey, India

045 **Paroxetine treatment does not effect testicular histology in rats**
Ege Can Serefoglu, Turkey
A. Gul, S. Altinay, D. S. Celik, A. Colakerol, E. Yuruk

046 **Evaluation of the fertility status of patients with lifelong premature ejaculation who were admitted to urology outpatient clinic**
Ege Can Serefoglu, Turkey
A. Colakerol, S. Calhan, E. Yuruk, M. Dincer

047 **Sensate focus exercise in newly-married men who ejaculates before intercourse**
Hongxiang Wang, China
T. Zhang, B. Chen, Y. Han, Y. Wang, Y. Huang

048 **Desensitization treatment for primary PE**
Hongxiang Wang, China
B. Chen, T. Zhang, Y. Han, Y. Wang, Y. Huang

049 **Over-sensitivity, a domain should not be ignore in PE**
Tao Zhang, China
Q. Yang, B. Chen, Y. Huang, Y. Huang, P. Ping, X. Chen, H. Wang, K. Hu, Y. Jin, Y. Wang, Y. Huang

050 **Combination of tamsulin (0.4 mg) and dutasteride (5 mg) for benign prostatic hyperplasia. Objective analysis of stromal components of the transition zone**
Andre Cavalcanti, Brazil
F. Sampaio, F. Restrepo, C. Gallo, B. Pereira, N. Machado, W. Costa

051 **Improvement in both lower urinary tract symptoms and erectile function with alpha blocker therapy in benign prostatic hyperplasia**
Christopher Ho, Malaysia
N. Ahmad Nazir, Z. Md Zainuddin

052 **Quantitative and qualitative analyses of stromal and acinar components of prostate zones**
Bruno Marroig, Brazil
F. Sampaio, B. Gregorio, C. Gallo, E. Alves, W. Costa

053 **Clinical correlates of enlarged prostate size in subjects with sexual dysfunction**
Elisa Maseroli, Italy
G. Corona, M. Gacci, G. Rastrelli, L. Vignozzi, A. Sforza, G. Forti, E. Mannucci, M. Maggi

054 **Characteristics of compensated hypogonadism in patients with sexual dysfunction**
Elisa Maseroli, Italy
G. Corona, G. Rastrelli, A. Sforza, G. Forti, E. Mannucci, M. Maggi

055 **Semen quality assessment in fertile men in spain during the last three decades**
José Medina-Polo, Spain
R.-O. Javier, B. García-Gómez, L.-P. David, E. Jiménez-Alcaide, L. García-González, A. Arrébola-Pajares, A. Rodríguez-Antolín, E. García Cruz

056 **The prostate after castration and hormone replacement in a rat model: Structural and ultrastructural analysis**
Alexandre Miranda, Brazil
B. Felix-Patricio, B. Gregorio, C. Gallo, D. Benchimol, W. Costa, F. Sampaio

057 **Development and recovery from secondary hypogonadism in aging men: Risk factors and clinical features. Prospective results from the european male aging study (EMAS)**
Giulia Rastrelli, Italy
E. Carter, J. Finn, S. Pye, M. Rutter, I. Huhtaniemi, N. Pendleton, G. Forti, M. Maggi, F. Wu

058 **Orgasmic function relies on testosterone levels – results of a cross-sectional study in men seeking medical attention for erectile dysfunction**
Eugenio Ventimiglia, Italy
P. Capogrosso, L. Boeri, A. Serino, G. La Croce, G. Castagna, A. Pecoraro, M. Paciotti, R. Scano, F. Montorsi, A. Salonia

059 **Development of a multivariate logistic regression-based nomogram to predict the presence of hypogonadism in patients with new-onset erectile dysfunction**
Eugenio Ventimiglia, Italy
P. Capogrosso, L. Boeri, A. Serino, G. La Croce, G. Castagna, A. Pecoraro, M. Paciotti, R. Scano, F. Montorsi, A. Salonia

Poster Presentations

060 **Gender disphorya and personality disorder: An investigation on comorbidity**
Sandri Federico, Italy
T. Bonavigo, P. Duccio, P.-F. Elisabetta, S. Elena, D. B. Lisa

061 **Transphobia and homophobia levels in general population, health care providers and in gender dysphoric individuals**
Alessandra Daphne Fisher, Italy
E. Fanni, H. Casale, G. Castellini, C. Meriggiola, V. Ricca, M. Maggi

062 **Possibilities of realization and fulfillment of the desire for reproduction in Czech lesbian women**
Pavel Turcan, Czech Republic
P. Pokorny, J. Kvintova, M. Sigmund, M. Prochazka

063 **The first analysis of the sigmoid neovaginal microbiota with IS-pro**
Wouter van der Sluis, The Netherlands
J. Meijerink, N. de Boer, A. van Bodegraven, M. Mullender, A. Budding, M.-B. Bouman

064 **Partnership status and quality of life of LGBT persons in Croatia**
Iva Zegura, Croatia
M. Jelic, N. Jokic-Begic, Z. Kamenov

065 **The greatest first step in acknowledging rights of transgender persons in Croatia – case report**
Iva Zegura, Croatia

066 **Gender differences and clinical evidence: Body shape perception and physical appearance stereotypes in obese people**
Giulia Botteon, Italy
T. Bonavigo, F. Sandri, L. Zagaria, W. Gerbino, E. Pascolo-Fabrici

067 **Psychosexological counseling in patients affected by bladder exstrophy-epispadias complex BEEC**
Massimo Di Grazia, Italy

068 **Measuring penile length from pubic bone to tip of glans is more accurate and reliable**
Mohamad Habous, Saudi Arabia
Z. Mekkawi, S. Mahmoud, K. Ali, J. Mulhall, B. Williamson, G. Muir

069 **Dynamic of sonographic parameters of prostate in depending from character of conducted antibacterial therapy**
Khalid Ibishev, Russia
M. Kogan, A. Paleoniy, A. Cherny, D. Krakhotkin

070 **Genesis of erectile dysfunction in patients with urethral structure**
Khalid Ibishev, Russia
M. Kogan, A. Paleoniy, D. Krakhotkin

071 **Analysis of sperm retrieval techniques in azoospermic men**
Christian Fuglesang Skjoedt Jensen, Denmark
D. A. Ohl, M. R. Hiner, M. Fode, T. Shah, G. D. Smith, J. Sonksen

072 **Characteristics of sexual function among healthy carriers of lrrk2 g2019s mutation first-degree relatives of patients with Parkinson**
Sharon Peleg Nesher, Israel
M. Ehrenfeld, T. Sagiv-Schfter, A. Mirelman, N. Giladi

073 **Who is taking care of sexual health education? Findings from a real-life survey in outpatients**
Alessandro Serino, Italy
E. Ventimiglia, P. Capogrosso, L. Boeri, G. La Croce, A. Pecoraro, M. Paciotti, M. Salonia, I. Camozzi, F. Montorsi, A. Salonia

074 **Organ sparing surgery in bilateral testicular tumour. Our initial experience**
Alberto Silva, Portugal
S. Lopes, A. Furtado, A. P. Cardoso

075 **The pronoun ‚hir' and other simple words as therapeutic tools**
Esben Esther Pirelli Benestad, Norway
R. Pristed

078 **Correction of veno-occlusive form of erectile disfunction**
Oleksandr Knigavko, Ukraine
V. Lesovoy, A. Arkatov, S. Kasiev

077 **The role of IGF-1 isoforms gene expression in peyronie's disease**
Charalampos Thomas, Greece
C. Psarros, A. Gkekas, M. Koutsilieris

079 **Study of sexual function in patients with prostate cancer prior laparoscopic radical prostatectomy**
Marta Capdevila, Spain
J. Muñoz, R. Martos, N. Hannaoui, J. L. Gonzalez, D. Garcia, J. Gual, Y. Fadil, A. Prera, C. Abad, J. Prats

080 **Mondor disease of the penis – observations on 8 cases**
Razvan Multescu, Romania
P. Geavlete

081 **Microsurgical selective neyrotomia vs long term SSRI**
Oleksandr Knigavko, Ukraine
V. Lesovoy, A. Arkatov

Poster Presentations

082 **The effects of ureteral dj stent applications in lower urinary tract symptoms and sexual function**
Mustafa Murat Aydos, Turkey
O. Gencoglu, S. Oner, M. H. Ustun, M. Kilic, M. Sambel, A. Erdogan

083 **Combination therapy with Triomen Quattro and meloxicam in the treatment of lower urinary tract symptoms (LUTS) and prostate pain syndrome (PPS)**
Aleksander Khelaia, Georgian

084 **Prediction of sexual dissatisfaction through the infrequency and avoidance of sexual encounters and anxiety**
Francisco Santamaria Cabello, Spain
F. J. Del Río Olvera, M. A. Cabello-García

085 **Varicocele open surgery or laparoscopy or embolization: Which is better?**
Mohamed Mourad Gargouri, Tunisia
Y. Ouanes, M. A. Ben Chehida, A. Sellami, M. Chelif, S. Ben Rhouma, Y. Nouira

P-02 FEMALE SEXUAL DYSFUNCTION

001 **Assessing the direction of causality between correlated subdomains of the female sexual function index**
Annika Gunst, Finland
A. Kärnä, P. Jern

002 **With a little help from my friends – self and social support in predicting sexual dissatisfaction among female medical students**
Tal Peleg-Sagy, Israel

003 **Impact of hysterectomy on female sexual quality of life**
Ieva Briedite, Latvia
G. Ancane, I. Rogovska, N. Lietuviete

004 **Sexuality in cystectomised women**
Josephine Rathenborg, Denmark

005 **Modern opportunities of esthetic gynecology for improvement of quality of sexual life of women**
Lina Shugusheva, Russia
B. Gvasalia

007 **Viewpoints on female virginity among students in Kosovo**
Hajrullah Fejza, Albania
I. Tolaj, S. Telaku, M. Alilaj, H. Reka, I. Reka

008 **Celibacy syndrome in Japan – culture specific. Phenomenon and clinical recommendations**
Dariusz P. Skowronski, Japan
M. Kobayashi, K. Waszynska, R. Kowalczyk

011 **Viveve treatment of the vaginal introitus to evaluate efficacy: A prospective, longitudinal, randomized, single-blind, sham controlled clinical study**
Michael Krychman, USA

012 **The viveve system is a non-invasive treatment for vaginal introital laxity that improve sexual function in adult female subjects**
Michael Krychman, USA

013 **Bladder endometriosis: Relevance of urinary symptoms in the diagnosis**
Dario Garcia-Rojo, Spain
N. Hannaou, A. Prera, C. Abad, E. Vicente, J. L. Gonzalez-Sala, R. Martos, J. Muñoz, M. Barrio, J. Prats

014 **Orgasmic behavior and the frequencies of sexual function disorders in 398 postpartum women in Istanbul**
Umit Sayin, Turkey
A. Kocaturk

015 **Correlation of good sexual relationships and satisfaction in marriage with the domestic violence in 398 postpartum women in Istanbul**
Umit Sayin, Turkey
A. Kocaturk

016 **Reconstruction of amputated labia minora after aesthetic labiaplasty by paraclitoral hood flaps**
Pieter Vermeulen, Belgium

017 **Menopause and perceived sexual response: Women's talk**
Fotini Ferenidou, Greece
L. Athanasiadis, K. Fokas, P.-S. Kirana, D. Hatzichristou

018 **Open-label cross-sectional study of sexual function in women of reproductive age, and women of older age**
Natalia Stenyaeva, Russia
D. Chritinin, G. Suchich

019 **Knowledge and attitudes of community pharmacists and pharmacy technicians in Kayseri, Turkey regarding emergency contraception**
Halil Tekiner, Turkey
M. Akar

Poster Presentations

020 **Assessment of sexual health in women with genital herpes**
Oksana Romashchenko, Ukraine
S. Melnykov, V. Bilogolovska, I. Kashchenko, S. Koval, N. Mironenko, M. Shcherbak, M. Hodzhava

021 **Analysis of the situation of male sex worker for women**
Ana Ruth Bernardo de Paz, Spain

022 **Obesity and sexual life: The body size impact**
Tommaso Bonavigo, Italy
C. Basile, E. Pascolo-Fabrici, F. Sandri

023 **Women's sexual response model in the reproductive age: A focus group study**
Fotini Ferenidou, Greece
L. Athanasiadis, K. Fokas, P.-S. Kirana, D. Hatzichristou

024 **Women's sense of insecurity as a trigger of sexual response: The role of sexual function and satisfaction**
Fotini Ferenidou, Greece
L. Athanasiadis, K. Fokas, P.-S. Kyrana, D. Hatzichristou

025 **Masturbation of healthy and type 1 diabetic males using the European male ageing study sexual function questionnaire**
Indre Matuleviciute, Lithuania
R. Ostrauskas, V. Urbanavicius, R. Verkauskiene, V. Matulevicius

026 **Sexual dysfunction and factors affecting sexual functions in pregnancy period**
Mustafa Murat Aydos, Turkey
S. Geylan, S. Oner, M. Kilic, M. Sambel, A. Erdogan

027 **Sexual dysfunction in type 2 diabetes predicts cardiovascular disease**
Samia Lotfy Laban Rizk, Canada

029 **Health services for women with sexual dysfunction: A survey of OBGYNs in Bavaria**
Megan McCool, Germany
S. Brandstetter, C. Apfelbacher

030 **Management of female sexual dysfunction: Knowledge, attitude and clinical experience of general practitioners and resident doctors in Dalarna, Sweden**
Maria Sundberg, Sweden
A. K Lindström

031 **Sexual orientation in adolescents and young adults**
Samia Lotfy Laban Rizk, CanadaW

Cases that Matter Presentations

P-03 CASES THAT MATTER POSTERS

001 **Post-traumatic high-flow priapism – case report**
Alberto Silva, Portugal

002 **Multidisciplinary approach in patients with complex sexual problems and comorbidities**
Boris Milkin, Russia

003 **Cryptorchism in 27 years old man with fertility issues**
Petya Angelova, Bulgaria

004 **Sexual functioning of patients with borderline personality disorder – cases**
Agata Lesnicka, Poland

005 **Masturbation of the woman with depressive symptoms**
Narine Nersisyan, Armenia

006 **Unlucky patient**
Maksym Romaniuk, Ukraine

007 **No medication? There is still psychotherapy! A case of successful therapy of vaginism in short-term psychodynamic psychotherapy**
Anatolijs Pozarskis, Latvia

008 **40 year old woman with anorgasmia arisen after quadrantectomia and radiation therapy for breast cancer associated with panic disorder**
Margherita Colombo, Italy

009 **Azoospermia in patient with left varicocele and hemicastration after right testicular cancer**
Aleksander Khelaia, Georgian

010 **Gender identity problem in a patient with an Asperger syndrome**
Vanda Lukacova, Czech Republic

011 **Impeding erosion of a penile prosthesis: A rare complication for which early treatment is indicated**
Charlotte J.M. Schillebeeckx, Belgium

012 **Laparoscopic radical prostatectomy in a patient with a prostate carcinoma and chronic pelvic pain syndrome. Disappearance of chronic pelvic pain symptoms and management of sequelae in the sexual area**
Dario Garcia-Rojo, Spain

013 **Misled by an erect penis?**
Anders Frey, Denmark

014 **Reconstructive surgery of genital giant condyloma – case report**
Sofia Lopes, Portugal

015 **Suicidal masturbation and erectile dysfunction**
Juliette Buffat, Switzerland

016 **Secondary hypogonadism in type 1 diabetic patient**
Maja Ravnik-Oblak, Slovenia

017 **HSDD as self-perceived problem – but what is the right diagnosis?**
Gabriella Gyovai, Hungary

018 **Late reproduction: A cause for male erectile and ejaculatory dysfunctions**
Ana Sofia Teixeira, Portugal

019 **Erectile dysfunction in Multiple Sclerosis – contributions of a multidisciplinary approach**
Susana Renca, Portugal

020 **Tight suspensory ligament**
Franklin Kuehhas, United Kingdom

021 **Two birds with one stone – ED vs BPH with Cialis**
Arik Shechter, Israel

022 **Stuttering priapism in a male with MEN1 syndrome**
Yaron Ofer, Israel

023 **Great balls of fire!**
Uri Gur, Israel

024 **Finally! Its time to treat refractory vaginismus with Botulinum toxin (BONT)**
Sanjay Pandey, India

025 **Sleep Related Painful Erection (SRPE) – a rare case**
Zita Beata Soos, Hungary

026 **Antipsychotic-induced priapism in an schizophrenic patient**
Visnja Banjac, Bosnia and Herzegovina

027 **Managing multiple risk taking as well as an erection**
Remziye Kunelaki, United Kingdom

028 **Persistan genital arousal syndrome or hypersexuality disorder**
Goran Arbanas, Croatia

029 **Penile disaster**
Artur Palmas, Portugal

031 **An inflatable penile prosthesis malfunction due to connection tubes rotation: A rare complication of the prosthetic surgery**
Marco Falcone, Italy

032 **A rare case of intra-abdominal migration of the reservoir of an inflatable penile prosthesis after revision surgery**
Amr Mohamed Abdel Raheem Mohamed, United Kingdom

033 **Hypersexual disorder and ED – a patient case**
Carl Leffler, Denmark

Cases that Matter Presentations

034 **Medical treatment of erectile dysfunction in a patient with Benign Prostate Hyperplasia and internet porn abuse**
Berit Tankred, Denmark

035 **Penile prosthesis implantation in a young patient can be a good choice**
Emmanuel Weyne, Belgium

036 **Cavernosal abscess and erectile dysfunction due to mixed aerobic-anaerobic infection**
Denis Krakhotkin, Russia

037 **Looking behind the family curtains – hypoactive sexual disorder in a full-time mother**
Dana Anais Muin, Austria

038 **Recurrent presentation for HIV post-exposure prophylaxis**
Shalini Andrews, United Kingdom

039 **Lehoczky island flap – is it an innovative and successful option in modern fistula repair?**
Noemi Bordas, Hungary
E. Holman, C. Maroti, J. Vancsura, F. Martins

040 **A surgical option for climacturia**
Eugenio Ventimiglia, Italy

041 **Polyorchidism: A rare condition which can be managed conservatively**
Abdullah Gül, Turkey

042 **The prostate as the gateway to men's health**
Jonny Coxon, United Kingdom

043 **Risky sexual behaviours in an adolescent girl who has bipolar disorder**
Veysi Çeri, Turkey

044 **Increases in bone mineral density in men with late-onset hypogonadism after 24 months of testosterone treatment**
Begoña Etcheverry Giadrosich, Spain

045 **Penile strangulation: How to manage a «donut» penile ring**
Victor Soulier, United Kingdom

046 **Man with ED, hypertension and Peroneyes treated with a combination of pharmacological and group therapy**
Kirsten Guldager, Denmark

047 **Male sexual dysfunction induced by military sexual assault**
Alexandre Kamnerdsiri, Czech Republic

048 **Malignant priapism: An unpleasant case for treatment**
Jose E. Robles, Spain

049 **Myotonic dystrophy type 1 (DM1) and hypergonadotropic hypogonadism: A clinical case**
Valentina Boddi, Italy

050 **Female penetration disorder with concomitant erectile dysfunction**
Mijal Luria, Israel

051 **A rare cause of erectile dysfunction: Retropubic ganglion cyst in the lesser pelvis**
Andreas Bannowsky, Germany

052 **Seminal vesicle cyst associated with ipsilateral renal agenesis causing post ejaculatory pain**
Peter Østergren, Denmark

053 **Stuttering priapism resistant even to shunt surgery in a 14-year old boy**
Sami Hayek, United Kingdom

054 **A sexually transmitted fixed drug reaction**
Ismael Maatouk, Lebanon

055 **Glans ischemia due to sponge fiber remained after the removal of wound dressing following circumcision**
Abdulmecit Yavuz, Turkey

056 **Erectile dysfunction caused by Congenital Adrenal Hyperplasia**
Mohamed Mourad Gargouri, Tunisia

057 **On-demand D-Modafinil may be an effective treatment option for lifelong premature ejaculation: A case report**
Ege Can Serefoglu, Turkey

058 **A new case of gender dysphoria in Klinefelter syndrome**
Alessandra Daphne Fisher, Italy

059 **Penile urethrocutaneous fistula following the placement of a Prince Albert piercing and subsequent PATIO repair**
Enrique Fes, United Kingdom

060 **Autoimmune autonomic ganglionopathy and erectile dysfunction – effect of plasmapheresis on sexual function**
Noam Kitrey, Israel

061 **Psychosexual outcomes of androgen replacement therapy in a patient with severe partial androgen insensitivity syndrome (PAIS)**
Elisa Maseroli, Italy

P-04 BEST CASES THAT MATTER POSTERS

001 **Erectile dysfunction: A window to the heart**
Vitaliy Androshchuk, United Kingdom

002 **Hyper sexuality and compulsive behaviors triggered by dopaminergic therapies in a case of Parkinson's disease**
Stefania Chiappini, Italy

003 **Sexual dysfunction caused by intrauterine device migration to the urinary bladder: A case report**
Konstantinos Dimitropoulos, Greece

004 **Malignant priapism secondary to urothelial cell carcinoma**
Francesco De Luca, United Kingdom

Workshops

5 February 2015

WS-01 **WORKSHOP**

08:30–10:00 **Auditorium 12**

Premature ejaculation, delayed ejaculation and anejaculation

Expert: Marcel Waldinger, The Netherlands
Chair: Ege Can Serefoglu, Turkey

Audience: The workshop has been designed for clinicians who treat men with complaints of premature ejaculation, delayed ejaculation and/or anejaculation.

The contents include three parts of each dysfunction:
1. The symptomatology of the disorder
2. The options for treatment
3. A number of clinical cases. Apart from application of evidence-based medicine proposed guidelines, the workshop will show that clinical experience is an important factor in diagnosis and treatment of these ejaculatory complaints, and that recommendations of guidelines may not always lead to disappearance of the complaint.

Aim: In daily clinical practice, a substantial number of patients do not present with textbook-like ejaculatory complaints. There might be comorbidity, patients may provide only minimal information of their complaints, or present with complaints that are related to non-ejaculatory disorders. In an interactive session, the audience will learn that a critical view towards official diagnostic criteria and treatment standards is a requirement for daily clinical practice with patients suffering from ejaculatory disorders.

Learning objectives
- To learn the subtle clinical symptoms of the four different premature ejaculation subtypes
- To learn the symptoms of primary and secondary delayed ejaculation and anejaculation
- To learn to differentiate between ejaculation-induced erectile dysfunction and other erectile disorders
- To learn how to deal with medication induced side effects
- To learn how to deal with non-responders

Summary of contents
There are four premature ejaculation subtypes, each with its own characteristic symptomatology. In addition, there are two types of delayed ejaculation, the well-known lifelong an acquired form. Although textbooks describe their symptoms, subtle characteristics have hardly been described as these subtle symptoms are often difficult to objectivate. Nevertheless, it are these subtle nuances that are important for a clinician for making a diagnosis that is based on clinical experience and scientific research. Although hardly investigated, also the two forms of delayed ejaculation and anejaculation can be recognized by symptoms that are not always presented in textbooks. The aforementioned subtle and subjective manifestations of ejaculatory disorders will be discussed in detail.

WS-02 **WORKSHOP**

10:00–11:00 **Auditorium 12**

Erectile dysfunction: Difficult cases

Expert: Dimitris Hatzichristou, Greece
Chair: Ilan Gruenwald, Israel

Audience: The workshop has been designed for physicians who treat regularly patients with erectile dysfunction. The contents include two parts: a) an introductory 20min "tips and tricks" session, and b) a number of well-designed clinical cases. The second part will allow the participants to understand why clinical experience is a significant complementary component of the evidence-based medicine.

Aim: In the everyday clinical practice, physicians deals with several challenging cases. Quite commonly, there are theoretically easy straightforward cases to deal with, however in reality we fail to manage such cases. Sexual history may not reveal the real cause(s) of the problem, existence of a co-morbidity leads us to characterize incorrectly a case as of organic origin, a diagnostic procedure may lead to false positive results and a typical treatment may not work. After presenting the principles and personal experience in the management of such cases, we will run a number of cases, where the audience will be asked to express their views. At the end of the workshop, we will summarize some critical steps "never-to-forget" in our everyday clinical practice.

Learning objectives
- To learn the secrets of the sexual history
- To learn how to differentiate the psychogenic component in organic cases
- To learn the secrets of the diagnostic procedures, e.g. triplex ultrasonography
- To learn how to evaluate non-responders to pharmacotherapy
- To learn how to treat truly non-responders
- To learn how to teach intracavernosal injections to your patients
- To discuss cases that treatment did not worked for them

Workshops

Summary of contents

Tips and tricks for the everyday clinical practice

Sexual history is difficult to learn. The physician may use typical questions to explore the problem. Several times however it is difficult to understand for example, if it is a problem of sexual desire or arousal. Or if it is an organic problem due to diabetes or the psychogenic consequences of diabetes. Even in organic cases, it is challenging to differentiate if the ultrastructural changes that lead to the dysfunction are permanent, or there is a way to restore them. Therefore, we will present the ways to identify the severity of each aetiological factor of the problem and an approach to treat each one of them. Diagnostic procedures on the other hand allows a more comprehensive work-up, however, as erectile mechanism is under control of the sympathetic nervous system, in many cases incomplete relaxation of the corporal smooth muscle may lead to a false diagnosis of vasculogenic ED, or to the diagnosis of severe vasculogenic ED in cases of mild or moderate vasculogenic problems. Methodologies to overpass the problem will be presented. Finally, in 30% of patients the PDE5 inhibitors do not work. Patient education, selection of the appropriate drug or dosages may solve the problem. We will present such practical tricks and salvage techniques. And if the solution is intracavernosal injection therapy, the steps to teach patients self-injecting without complications is easy. A step-wise practical approach will be discussed in details.

WS-03 **WORKSHOP**

11:00–12:00 **Auditorium 12**

Genital surgery – how to avoid complications

Experts: David Ralph, Giulio Garaffa, United Kingdom
Chair: Fabrizio Palumbo, Italy

Aim: Complications in all surgery occur. The aim is to reduce their incidence and be able to manage them quickly and effectively and thereby minimise the usual poor outcome. With increasing experience, surgeons learn from their mistakes and are therefore more likely to know how to avoid specific complications. Avoidance of genital surgery complications is discussed in this workshop.

Learning objectives

- To identify the correct operation for the patient
- To give patients realistic expectations
- Informed consent is imperative
- To identify specific issues in Peyronie's surgery and penile implants that will help in minimising early and late complications
- To discuss common genital operations that frequently are associated with complications

Summary of contents

Peyronie's surgery / Giulio Garaffa, 20 min
Indications, expectations and consent
Complication prevention – shortening, recurrent curvature, ED, foreskin issues, sutures

Penile prosthesis / Fabrizio Palumbo, 20 min
Indications, expectations and consent
Complication prevention – infection, erosion, positioning, revision surgery, deformities

Penile reconstruction / David Ralph, 20 min
Complication prevention in – augmentation surgery, skin grafting, circumcision

6 February 2015

WS-04 **WORKSHOP**

08:30–10:00 **Auditorium 12**

Hormonal difficulties in men and women

Experts: Mario Maggi, Linda Vignozzi, Italy
Chair: Giovanni Corona, Italy

Audience: The workshop has been designed for physicians and sexologists who regularly treat patients with sexual dysfunction. The lecture includes two parts: the first one deals with the contribution of the endocrine system in the physiology and pathophysiology of male sexual problems. The second part is on female sexual dysfunction. A series of clinical cases would be presented in order to involve the audience in the right evidence-based choice.

Aim: Hormones represent one of the most common forms of sexual communication. Therefore, when sexual communication is problematic, such as in the case of endocrine disorders, investigating sexual dysfunction is mandatory. Many endocrine disorders, or their treatments, are characterized by several alterations in sexual response. Endocrine disorders are usually considered easy to diagnose and often-remediable, however, they frequently receive little attention. In addition, it should be recognized that the assessment of endocrine disorders can uncover serious diseases, such as pituitary tumors, or can help in stratifying the CV risk of ED patients. All these points would be analyzed during the presentations and specific practical take home messages would be delivered.

Learning objectives

- To learn the role of the endocrine system in the physiology of male and female sexual responses
- To learn how to recognize the symptoms and signs of the most important endocrine diseases involved in the pathogenesis of male and female sexual dysfunction

Workshops

- To learn how to diagnose the most important endocrine diseases involved in the pathogenesis of male and female sexual dysfunction
- To learn how the correction of the endocrine problem might improve male and female sexual function
- To learn the possible outcomes of combinations between endocrine therapy and traditional therapies used for the treatments of male and female sexual dysfunction

Summary of contents

Tips and tricks for the everyday clinical practice

Hormone alterations can be involved in determining sexual dysfunction both in men and women, or they can be the consequence of sexual problems, often with a bidirectional interconnection. In particular, the most frequently reported endocrinopathies in men are hypogonadism, hyperprolactinemia and hypothyroidism whereas hyperthyroidism is less often associated with sexual dysfunction. Testosterone has a pivotal role in regulating several aspects of the male sexual response, and its deficiency is probably the underlying cause for a consistent portion of male sexual dysfunctions. Despite this evidence, the widespread screening for hypogonadism in subjects with sexual dysfunction, and the role of testosterone supplementation as a possible treatment, still remains questionable. The association between severe hyperprolactinemia and male reduced sexual desire is well known. Conversely, the role of prolactin in the pathogenesis of erectile dysfunction is still conflicting. Obesity and type 2 diabetes mellitus (T2DM) are common metabolic disorders. Male subjects with sexual dysfunction represent a population overloaded with these conditions, which contributes to increasing the overall high cardiovascular risk as well to the increased prevalence of hypogonadism. On the contrary, evidence regarding the association between metabolic diseases and female sexual dysfunction are less conclusive, although most studies documented a higher prevalence of female sexual dysfunction in diabetic women as compared to non-diabetic ones. Female sexual function appears to be more related to psychosociological issues than to the organic consequence of diabetes. Chronic hyperprolactinemia is classically associated with hypogonadotropic hypogonadism and sexual dysfunction also in females and its successful treatment generally normalizes sexual function. In addition, in females, menopause with a progressive decline of sex steroid hormones as well as the aging process associated with many psychological stressors, modulate vulnerability for sexual symptoms (hypoactive sexual desire, reduced arousal and lubrication, dyspareunia, orgasmic dysfunction and lack of satisfaction). Among all these symptoms the most common one is decreased libido.

WS-05 **WORKSHOP**

11:00–12:00 **Auditorium 12**

Title: Infertility and sexuality

Experts: Ates Kadıoglu, Turkey, Natalio Cruz Navarro, Spain, Johannes Bitzer, Switzerland

Chair: Natalio Cruz Navarro, Spain

Audience: Workshop designed for physician and psychologist who deal with sexuality or infertility. Content divided in 2 section according to gender of the patients. The influence of both sexuality and infertility on the patient and each other will be addressed.

Aim: Although a bidirectional link is accepted to exit between infertility and sexual dysfunction, only 5% of the infertility cases are caused by sexual dysfunction. While erectile dysfunction and inability to ejaculate are infertility causes of male origin, vaginismus is only infertility reason originating from female sexual dysfunction (FSD). However both infertility treatment and the disease itself have a great negative impact on the sexual life of infertile couples. The causality relationship of infertility and SD is hypothesized to be depending on the loss of sexual spontaneity, direct linkage of sex into pregnancy without entertainment, decreased self-esteem and body image of the individuals. In addition the inter-relationship problems and the possible negative influence of hormonal treatment aggravates the sexual dysfunction problem. The aim of this workshop is to increase the urologists' awareness about this cause-effect relation and furthermore prepare our colleagues for the diagnosis and prevention of this disease.

Learning objectives

- The awareness of the bidirectional link of sexual dysfunction and infertility
- Assessment and prevention of possible risk factors
- Investigating both male and female aspects of this phenomena
- Diagnosis and management of sexual dysfunction in infertile couples
- Update the literature knowledge of the attendees about the subject
- Application of the obtained skill set to their clinical practice

Summary of contents

Moderator: Ates Kadıoglu, Turkey

- Male infertility and sexual dysfunction (prevalence, diagnosis, treatment) / Natalio Cruz Navarro, 25 min
- Female infertility and sexual dysfunction (prevalence, diagnosis, treatment) / Johannes Bitzer, 25 min
- Questions-Answers, 10 min

Workshops

7 February 2015

WS-06 **WORKSHOP**

09:00–10:00 **Auditorium 12**

Vulvodynia, vestibulodynia and sexual pain disorders (diagnosis, examination and treatment)

Experts: Johannes Bitzer, Switzerland, Lior Lowenstein, Israel, Gidenon Sartorius, Switzerland
Chairs: Johannes Bitzer, Switzerland, Lior Lowenstein, Israel

Audience: The workshop is designed for physicians, physiotherapist, psychologists involved in the care for women who complain about provoked and unprovoked pain in the vulvar region as well as those women who suffer from dyspareunia.

Aim: Present and discuss standard operating procedures for care by giving background evidence based information, showing and discussing gaps in knowledge and how to handle these gaps in clinical practice, apply knowledge and skills some case discussion.

Learning objectives

- To learn: How to encourage patients to talk about complaints in an intimate region and pain related to sexuality; Understand and differentiate the clinical entities and the diagnostic categories and apply a diagnostic algorithm, know about the biological, psychological and interactional causes of the symptoms and know how to assess them. Find solutions in a process of shared decision making
- To be able to care for these patients in a patients centered individualized way

Summary of contents

Knowledge: Clinical entities, classification, diagnostic algorithm, SOPs, therapeutic options
Skills: Communication, questions to ask, examination
Attitude: Patient centeredness, empathy, patience

WS-07 **WORKSHOP**

11:00–12:00 **Auditorium 12**

How to improve patients' satisfaction and compliance

Expert: John Dean, United Kingdom
Chair: Paraskevi-Sofia Kirana, Greece

Audience: Physicians and psychologists treating men and women with sexual dysfunctions.

Aim: To help clinicians tailor their daily clinical practice in ways that improve patient's satisfaction and compliance with medication and treatment strategy.

Learning objectives

- To understand the significance of treatment satisfaction and compliance in the field of sexual medicine
- To understand the relationship between satisfaction and compliance
- To recognize factors that lead to non compliance and low treatment satisfaction
- To become familiar with practical skills that improve patients' satisfaction and compliance

Summary of contents

Compliance with treatment strategies is a very important clinical issue in sexual medicine. In prescribing medication, compliance means "the extent to which the patient takes the medication as prescribed". Many organic sexual dysfunctions require life long medication use, while in psychogenic cases, medication use is often intended to gradually decrease as patients become more competent. Although significant advances in medications have been made for the treatment of sexual dysfunctions, non compliance rates are very high, and this often leads to relapse, disappointment and low treatment satisfaction. It must be noted, that in many cases, non compliance refers not only to under use but also overuse of medication. Therefore, enhancing compliance (or preventing noncompliance) is an important treatment goal for patients and clinicians. In addition, sexual dysfunctions that require non pharmacological treatment methods have high drop out rates. The following categories of factors that affect treatment satisfaction and compliance will be discussed: Patient characteristics, the treatment setting, treatment characteristics, clinical features of the dysfunction/disorder, clinician expertise. Although knowledge of these factors is the first step, it is not enough to improve patient's compliance and satisfaction. Other steps include the establishment of a strong alliance with the patient, patient education about the dysfunction and the importance of maintenance treatment, patient education about the medication, drug interactions, pharmacokinetics and side effects, costs etc, combining medication prescription with sexuality education aiming to enhance the effectiveness of medication. Part of the workshop will address specific ways to improve compliance and satisfaction respectively, for each of the most common sexual dysfunctions of men and women.

General Information

CONGRESS VENUE

Bella Center
Center Boulevard 5
2300 Copenhagen S
www.bellacenter.dk

CONGRESS REGISTRATION COUNTER

All congress materials and documentation will be available at the congress registration counter located in the entrance area of the Bella Center. The congress staff will be pleased to help you with all enquiries regarding registration, congress material and congress program. Please do not hesitate to contact the staff members if there is anything they can do to make your stay more enjoyable.

Opening Hours

Thursday, 5 February 2015	07:30 – 18:00
Friday, 6 February 2015	08:00 – 18:00
Saturday, 7 February 2015	08:00 – 18:00

During opening hours the congress counter can be reached by phone at: +45 – 32 – 472952

REGISTRATION FEES

Registration fee for participants includes:

- Admission to all scientific sessions and workshops
- Admission to poster and technical exhibition
- Admission to the ESSM opening ceremony and networking reception on 5 February 2015
- Conference materials, such as delegate bag, final program
- Morning and afternoon coffee breaks from Thursday to Saturday

CONGRESS FEES

Registration and Payment	from 21 Oct 2014
ESSM members, physicians (MD)	EUR 600
Non-members, physicians (MD)	EUR 700
ESSM members with reduced fees*: Nurses, residents in training, scientists (Phd), psychologists, therapists, students	EUR 250
Non-members with reduced fees*: Nurses, residents in training, scientists (Phd), psychologists, therapists, students	EUR 300

* A letter of the chairman of the department is necessary.

CONGRESS LANGUAGE

The congress language is English. Simultaneous translation will not be provided. Symposia in national languages organized by the National Affiliated Societies (NAS) will be offered in a dedicated room throughout the congress days.

PUBLICATIONS FOR PROCEEDINGS

The European Society for Sexual Medicine retrains the right to publish all material presented at the congress in an ESSM publication.

ABSTRACT PUBLICATION

Accepted abstracts that are presented during the congress will be published in the online JSM supplement available from end of March 2015. Accepted abstracts that are not presented by the author or a presenter will not be published in the JSM online supplement.

Abstracts will also be published in CO CONGRESS ONLINE® from one day prior to the congress (4 February 2015) on the congress website and on CONGRESS MOBILE®, the congress app.

CO CONGRESS ONLINE®

For the 17th ESSM Congress 2015 the web based congress information system CO CONGRESS ONLINE® has been set up again at www.essm-congress.org.

CO CONGRESS ONLINE® offers an extensive congress service and provides you with information on:

- Up-to-date information about the preparation of the congress
- List of topics
- Call for oral presentations and posters
- Preliminary and final scientific program
- Accepted abstracts
- List of exhibitors
- Acknowledgements of sponsors
- Congress venue
- City of Copenhagen
- Hotel accommodation
- Travel to Copenhagen
- News

General Information

SPEAKERS CENTRE

The speakers centre is located in room 16 on level 1 of the Bella Center. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their presentation but at least 90 minutes prior to the presentation. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Several PC working stations are provided in the speakers centre where speakers can also work on their PC charts in a quiet area. Technical staff will be glad to assist.

Opening Hours

Thursday, 5 February 2015	07:30 – 18:00
Friday, 6 February 2015	08:00 – 18:00
Saturday, 7 February 2015	08:00 – 18:00

Operated by Estensis GmbH – the Conference Company

ESTENSIS
The Conference Company.

ESSM 2015 APP CONGRESS MOBILE®

Get the ESSM 2015 congress app for your smart phone now and experience the congress at your fingertips! Stop carrying around piles of paper and quickly find your way through the most up-to-date congress schedule. Just take the congress with you, wherever and whenever you want! The app is completely free and provides iPhone/iPad and android users at ESSM 2015 in Copenhagen with on-the-go access to the schedule and vital information around the congress.

ESSM 2015

Powered by GLOBIT's acclaimed CONGRESS MOBILE® software.

Further information is given at
www.essm-congress.org/app

WIRELESS LAN

As a courtesy to all participants wireless LAN in the exhibition area allows easy access to the internet. Please select WiFi network (SSID) **ESSM2015**.

ESSM MEMBERSHIP ISSUES

For ESSM membership issues and any other ESSM business, please contact our ESSM booth which is situated in the exhibition hall A1 of the Bella Center.

NAME BADGES

All participants are kindly requested to wear their name badges at all times during the congress. The colors of the name badges have the following significance:

Congress delegate:	blue
Press:	yellow
Exhibition:	green
Staff:	red

TECHNICAL EXHIBITION

The technical exhibition will be situated in the exhibition hall A1 of the Bella Center. Coffee bars will be located in the technical exhibition.

Opening Hours

Thursday, 5 February 2015	10:00 – 20:00
Friday, 6 February 2015	08:30 – 17:00
Saturday, 7 February 2015	08:30 – 17:00

POSTER EXHIBITION

Posters, highlighted posters and case presentations will be sited in the Hall A1 of the Bella Center.

ESSM highlighted poster tours will take place during the coffee breaks on Thursday, Friday and Saturday. Each poster tour includes seven poster presentations chaired by two senior scientists. For further information please see from page 33 of the scientific program.

Opening Hours

Thursday, 5 February 2015	10:00 – 20:00
Friday, 6 February 2015	08:30 – 17:00
Saturday, 7 February 2015	08:30 – 17:00

General Information

COFFEE BREAKS AND LUNCHES

Coffee and tea will be served during the morning and afternoon, daily from Thursday, 5 to Saturday, 7 February 2015 free of charge to all participants wearing congress name badges. A daily snack lunch as well as coffee breaks will be served in the Hall A1. The congress venue also provides a restaurant in the adjacent restaurant of the Bella Sky Hotel.

CLOAKROOM

A cloakroom free of charge is available in the entrance area of the Bella Center. Delegates can also store their luggage here.

EMERGENCY AND FIRST AID

In the case of emergency please address the staff at the registration counter in the entrance area of the Bella Center. The attentive staff will be pleased to help.

RECORDING

Cameras, video cameras or audio recording devices are not permitted in the session rooms. Any recording of sessions is strictly forbidden.

SMOKING

The Bella Center is a non-smoking venue. Smoking is prohibited within the congress venue.

VISA

The entry formalities for Denmark vary according to the country of origin. Please address enquiries about entry and vaccination to your travel agent or the local Danish consulate. Further information can also be found at http://um.dk/en/travel-and-residence/danish-visa-rules/

INSURANCE

The congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of origin.

FORCE MAJEURE

For reasons beyond its control (such as war, strikes, lockouts, riots or any such civil disturbances, any acts of god, including but not limited to earthquakes, floods, droughts and typhoons and any other cause of circumstance of whatsover nature beyond control) that have an impact on the arrangements, timetables or planning of the 17th Congress of the European Society for Sexual Medicine and its corresponding activities in Copenhagen, Denmark, ESSM has the right to immediately alter or cancel the activities or events or any of the arrangements, timetables, plans or other items relating directly or indirectly thereto. No party involved shall be entitled to any compensation for damages that result from such alteration or cancellation.

TIME

During winter time from November to March the time zone in Denmark is CET (Central European time).

CURRENCY

The 'krone' (DKK) is the official currency of Denmark. Exchange rate: 1 EUR = 7,44 DKK (January 2015). Major credit cards are generally accepted by most of the hotels, restaurants and shops.

CLIMATE

In general Denmark can be very windy since it is a coastal country. Winters are long, dreary and cold.

BANK AND ATM

Most banks in Denmark have automated teller machines (ATMs) that give cash advances on Visa and MasterCard credit cards as well as Cirrus and Plus bank cards. Although ATMs are accessible outside normal banking hours, not all are open 24 hours; particularly outside of Copenhagen.

ELECTRICITY

The local voltage is 230 V with C&F plugs. A voltage converter and plug adapter is needed for US appliances.

General Information

BELLA CENTER

The 17th ESSM Congress will take place in the Bella Center which is known as one of the number one exhibition, congress and convention centres in Scandinavia, and located in the surroundings of the Copenhagen city centre.

COPENHAGEN

Copenhagen has a history as being one of the great design capitals of the world with some of the world's most stunning modern architecture and interiors. A one thousand year history, tales from the oldest monarchy in the world, fairy tale writing and celebrated international designers await the delegates in the medieval streets, 17th century canals, and modernist architecture of Copenhagen.

TRAVEL TO COPENHAGEN AND BELLA CENTER

By plane

Copenhagen is easy accessible from many European airports with direct flight connections. It is the largest airport in Scandinavia. The city centre is only 13 minutes away by metro or train. From Copenhagen Airport it takes 10 minutes to reach the Bella Center. A regional train runs from the airport to Ørestad Station, the station of the Bella Center.

By train

Copenhagen Central Station is located in the heart of the city, bordering to the rough but also trendy Vesterbro. It is a gateway to all public transportation in and out and around Copenhagen. From Copenhagen Central Station it takes approx. 10 minutes by metro to reach the Bella Center. The name of the metro station is Bella Center.

By car

Bella Center is located at
Center Boulevard 5, 2300 Copenhagen S.

Follow the „Airport Motorway", E20. The exit to Center Boulevard is number 19 and is called „Ørestad" with „Bella Center" listed below.

PUBLIC TRANSPORTATION IN COPENHAGEN

The public transportation in Copenhagen is reliable, punctual, and it goes everywhere in the city. In Copenhagen the trains, metro and busses (including waterbuses) can be accessed with the same ticket. All you need to know is how many zones you will pass on your journey. Note the metro will take you from the airport to central Copenhagen in only 20 minutes.

TAXIS TO BELLA CENTER

Bella Center is just a 10–15 minutes' taxi drive from Copenhagen Central Station and not more than 10 minutes from Copenhagen Airport by taxi. A taxi from Bella Center to the city centre costs about DKK 200. A taxi from Bella Center to Copenhagen Airport costs about DKK 150–200.

Overview of Meeting Rooms

Ground Floor



First Floor





References: 1. Hellstrom WJG *et al.* BJU Int 2012; 111: 137-147. 2. Goldstein I *et al.* J Sex Med 2012; 9 (4): 1122-1133.

▼Spedra; 50mg, 100mg and 200mg tablets
ABBREVIATED PRESCRIBING INFORMATION

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.
Please consult the Summary of Product Characteristics (SPC) for full prescribing information.

Presentation: Tablets containing 50 mg, 100 mg or 200 mg of avanafil.
Use: Treatment of erectile dysfunction in adult men. In order for Spedra to be effective, sexual stimulation is required.
Dosage: Oral administration. Adult men: Recommended dose 100 mg, taken as needed, approximately 30 minutes before sexual activity. Dose may be increased to a maximum dose of 200 mg or decreased to 50 mg. Maximum recommended dosing frequency is once per day. No dose adjustment needed for older men, mild to moderate renal impairment or diabetes. Initiate treatment at minimum efficacious dose and adjust posology based on tolerance for mild to moderate hepatic impairment. Maximum recommended dose should not exceed 100 mg with concomitant treatment with moderate CYP3A4 inhibitors, leaving at least 48 hours between doses. If taken with food, the onset of activity may be delayed compared to the fasted state.
Contraindications: Hypersensitivity to active substance or excipients. Patients using any form of organic nitrate or nitric oxide donors. Consider potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease before prescribing. Contra-indicated in myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; resting hypotension (<90/50 mmHg) or hypertension (>170/100 mmHg); unstable angina, angina with sexual intercourse, or congestive heart failure. Severe hepatic or renal impairment. Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy. Known hereditary degenerative retinal disorders. Potent CYP3A4 inhibitors.
Warnings and Precautions: Undertake medical history and physical examination to diagnose erectile dysfunction and determine potential underlying causes, before considering pharmacological treatment. Consider the cardiovascular status of patients before initiating treatment. Instruct patients who experience priapism to seek immediate medical assistance. Use with caution in patients with anatomical deformation of the penis or conditions which may predispose them to priapism. Advise patients to stop taking Spedra and consult a physician immediately if sudden visual effects occur. No safety information in patients with bleeding disorders or active peptic ulceration, therefore administer to such patients only after careful benefit-risk assessment. Advise patients to stop taking PDE5 inhibitors, including avanafil, and seek prompt medical attention in event of sudden decrease or loss of hearing. Concomitant use with alpha-blockers may lead to symptomatic hypotension in some patients. Co-administration with potent inhibitors of CYP3A4, such as ketoconazole or ritonavir is contraindicated. Concomitant use of other treatments for erectile dysfunction has not been studied, thus inform patients not to take avanafil in such combinations. Advise patients concurrent use of avanafil and alcohol may increase the likelihood of hypotension, dizziness or syncope. Not studied in erectile dysfunction due to spinal cord injury or other neurological disorders and in subjects with severe renal or hepatic impairment.
Interactions: Administration with organic nitrate or nitric oxide donor contraindicated. May cause symptomatic hypotension with medicinal products which reduces systemic blood pressure. Alpha-blockers, other antihypertensives, alcohol. Moderate CYP3A4 inhibitors - maximum recommended dose 100 mg, do not exceed once every 48 hours. Avoid grapefruit juice within prior 24 hours. Concomitant use with CYP inducers not recommended. Please consult the SPC for more details and other interactions.
Side-effects: Common (1-10%): headache, flushing, nasal congestion. Uncommon (0.1- 1%): dizziness, somnolence, sinus headache, blurred vision, palpitations, hot flush, sinus congestion, exertional dyspnoea, dyspepsia, nausea, vomiting, stomach discomfort, back pain, muscle tightness, fatigue, hepatic enzyme increased, electrocardiogram abnormal, heart rate increased. Rare (0.1-0.01%): influenza, nasopharyngitis, seasonal allergy, gout, insomnia, premature ejaculation, inappropriate affect, psychomotor hyperactivity, angina pectoris, tachycardia, hypertension, rhinorrhoea, upper respiratory tract congestion, dry mouth, gastritis, lower abdominal pain, diarrhoea, rash, flank pain, myalgia, muscle spasms, pollakiuria, penis disorder, spontaneous penile erection, genital pruritus, asthenia, chest pain, influenza like illness, peripheral oedema, blood pressure increased, blood urine present, cardiac murmur. Increased PSA, weight, blood bilirubin, blood creatinine and body temperature.

Marketing Authorisation Number: Spedra 50 mg: EU/1/13/841/001-003; Spedra 100 mg: EU/1/13/841/004-007; Spedra 200 mg: EU/1/13/841/008-010. Marketing Authorisation holder: Menarini International Operations Luxembourg S.A. 1, Avenue de la Gare, L-1611 Luxembourg, Luxembourg. Date of first authorisation: 21 June 2013. For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder. Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu

Licenced by Vivus Inc. and Mitsubishi Tanabe Pharma Corporation.

the MENARINI group

List of Exhibitors/Exhibition Plan

By company name

Company	Booth No.
American Medical Systems	6
Astellas Pharma A/S	8
BSSM – British Society for Sexual Medicine	17
Coloplast A/S	9
Direx GmbH	11
Dornier MedTech Europe GmbH	5
EFS – European Federation of Sexology Congress 2016	12
ESSM – European Society for Sexual Medicine	1
GETA Centrum s.r.o.	13
ISSM – International Society for Sexual Medicine	16
Medispec Ltd.	10
Menarini Group	2
MTS Medical UG	14
Sandoz A/S	19
STORZ MEDICAL AG	3
ZSI (Zephyr Surgical Implants)	15

By booth number

Booth No.	Company
1	ESSM – European Society for Sexual Medicine
2	Menarini Group
3	STORZ MEDICAL AG
5	Dornier MedTech Europe GmbH
6	American Medical Systems
8	Astellas Pharma A/S
9	Coloplast A/S
10	Medispec Ltd.
11	Direx GmbH
12	EFS – European Federation of Sexology Congress 2016
13	GETA Centrum s.r.o.
14	MTS Medical UG
15	ZSI (Zephyr Surgical Implants)
16	ISSM – International Society for Sexual Medicine
17	BSSM – British Society for Sexual Medicine
19	Sandoz A/S

Exhibition Plan, Hall A1



Acknowledgements

The organizers of the 17th Congress of the European Society for Sexual Medicine gratefully acknowledge the support of the following companies (as per January 2015).

MAJOR SPONSOR

Menarini

SPONSORS

- American Medical Systems
- Astellas A/S
- Bayer Healthcare
- Coloplast A/S
- Eli Lilly and Company
- Evolan Pharma AB
- Direx GmbH
- Dornier MedTech Europe GmbH
- GETA Centrum s.r.o.
- Ferring
- Medispec Ltd.
- MTS Medical UG
- Sandoz S.A.
- STORZ MEDICAL AG
- ZSI (Zeyphyr Surgical Implants)

1995 – 2015

SA-01 SATELLITE SYMPOSIUM

12:30–13:30 **Auditorium 15**

Innovations in prosthetic surgical techniques

Chairs: David Ralph, United Kingdom
Juan Ignacio Martinez-Salamanca, Spain

Erectile restoration: "Innovative, retractor-less approach to penoscrotal placement and unique aspects of the streamlined Infrapubic placement of the AMS 700 penile prosthesis"
Lawrence Hakim, USA

Erectile restoration: "Managing erectile dysfunction with concurrent Peyronie's disease in 2015 using penile prosthetics"
Tony Bella, Canada

Male continence: "Surgical solutions for all degrees of male stress urinary incontinence"
Ignacio Moncada, Spain

Supported by an unrestricted educational grant from American Medical Systems

VS-01 VIDEO SESSION

13:30–15:30 **Auditorium 15**

Surgical treatment of male infertility and sexual dysfunction

Chairs: Ates Kadioglu, Turkey
Salvatore Sansalone, Italy

001 **Peyronie's disease**
Javier Romero Otero, Spain

002 **Congenital penile deviation**
Natalio Cruz, Spain

003 **Challenging cases in penile implant surgery**
Carlo Bettocchi, Italy

004 **Penoplasty and complementary procedures: Step-by-step**
Alessandro Littara, Italy

005 **Lengthening and girth restoration with penile prosthesis implantation without graft**
Paulo Egydio, Brazil

006 **Microsurgical varicocele repair**
Dana Ohl, USA

007 **Micro-TESE**
Joaquin Sarquella, Spain

008 **Bilateral impending distal erosion treated by bilateral distal re-tunnelling upon penile MRI guidance**
Edoardo Pescatori, Italy

Supported by an educational grant from Coloplast A/S

CM-01 CASE SESSION

15:30–16:30 **Auditorium 15**

Cases that matter 1

Chairs: David Ralph, United Kingdom
Hartmut Porst, Germany
Yacov Reisman, The Netherlands

001 **Erectile dysfunction: A window to the heart**
Vitaliy Androshchuk, United Kingdom

002 **Hyper sexuality and compulsive behaviors triggered by dopaminergic therapies in a case of Parkinson's disease**
Stefania Chiappini, Italy

003 **Sexual dysfunction caused by intrauterine device migration to the urinary bladder: A case report**
Konstantinos Dimitropoulos, Greece

004 **Malignant priapism secondary to urothelial cell carcinoma**
Francesco De Luca, United Kingdom

Supported by an educational grant from Eli Lilly and Company

Industry Sessions I Friday 6 February 2015

LV-01 **LIVE SURGERY**

08:30–12:00 **Auditorium 15**

Male sexual dysfunction

Chairs: David Ralph, United Kingdom
Javier Romero Otero, Spain

001 **Surgeon in operation room #1**
Giulio Garaffa, United Kingdom

002 **Surgeon in operation room #1**
Evangelos Zacharakis, United Kingdom

Chairs: Sebastian Beley, France
Daniar Osmonov, Germany

003 **Surgeon in operation room #2**
Dana Ohl, USA

004 **Surgeon in operation room #2**
Lasse Fahrenkrug, Denmark

Live broad cast from Herlev hospital

Supported by an educational grant from Coloplast A/S

RT-06 **ROUND TABLE**

10:30–12:00 **Auditorium 10/11**

Bench-to-bedside: Premature ejaculation – a translational update 2015

Chairs: Patrick Jern, Finland
Onder Yaman, Turkey

001 **Central and serotoninergic origins of PE**
Francois Giuliano, France

002 **Genomic alterations in lifelong premature ejaculation**
Paddy Janssen, The Netherlands

003 **Peripheral manipulations for premature ejaculation**
Ege Can Serefoglu, Turkey

004 **New molecular targets in the hormonal control of ejaculation. Where are we running?**
Emmanuele A. Jannini, Italy

Supported by an educational grant from the Menarini Group

SA-02 **SATELLITE SYMPOSIUM**

12:30–14:00 **Auditorium 15**

ED and PE: *Disputationes* on male and female perspectives

Chair: Vincenzo Mirone, Italy

Opening Lecture – ED and PE: State of the art
Vincenzo Mirone, Italy

PE: Male and female perspectives
Chris McMahon, Australia
Alessandra Graziottin, Italy

ED: Male and female perspectives
Hartmut Porst, Germany
Andrea Burri, Switzerland

Q&A and closing remarks
Vincenzo Mirone, Italy

Industry sponsored satellite symposium by the Menarini Group

RT-16 **ROUND TABLE**

16:00–17:15 **Auditorium 15**

State of the art in intracavernosal injection therapy for PDE5-inhibitor nonresponders

Chair: Geoffrey Hackett, United Kingdom

001 **The history of penile injection therapy – past present and future**
Ronald Virag, France

002 **Office work-up of PDE5-inhibitor failures**
Andrea Salonia, Italy

003 **Molecules for injection: Pharmacological properties and potential benefits**
Stefan Arver, Sweden

004 **The clinican's stand point: Experience with injection therapy**
Hans Joergen Kirkeby, Denmark

Supported by an educational grant from Evolan Pharma

ESSM

European Society for Sexual Medicine

The European Society for Sexual Medicine (ESSM) is a not-for-profit, multidisciplinary, academic and scientific organisation dedicated to male and female sexual health and dysfunction.

Benefits from Becoming an ESSM Member

- ESSM offers its members a permanently updated web-site with different forums and a monthly update of the whole scientific literature of Sexual Medicine, Andrology and related medical disciplines.
- ESSM provides its members quarterly newsletter, ESSM Today which features the most recent news in the field of Sexual Medicine and focuses on key topics of interest to physicians in the field.
- ESSM has supported the creation of the Multidisciplinary Joint Committee on Sexual Medicine (MJCSM) that is working under the auspices of the European Union of Medical Specialists (UEMS). MJCSM's objectives are to study, promote and harmonize the highest level of Sexual Medicine in Europe – both on the basic and postgraduate level. The MJCSM will determine the standards for training and assessment in Sexual Medicine. Successful candidates will be awarded on behalf of the MJCSM the title of "Fellow of European Committee on Sexual Medicine (FECSM).
- Since 2007 ESSM has offered interested ESSM members the participation in a course of the European School of Sexual Medicine. Since 2013 the course is held in Budapest with the participation of more than 30 students from all over the world, supervised by the School Directors Yacov Reisman and Francesca Tripodi.
- Besides this structured course ESSM offers at its annual congresses tailor-made workshops covering the key contents of the ESSM educational program.
- ESSM provides to its members important research grants which all members are welcome to apply for according to eligibility criteria. These are intended to further research into any aspect of Sexual Medicine and are awarded with a maximum of EUR 30.000,00 each for a maximum of 18 months project duration.
- ESSM recognizes that basic scientists who are not actively engaged in clinical work in sexual medicine field may have had difficulty finding funds to attend the ESSM Annual Congresses and therefore awards a number of free registration and travel funds.
- Fellowship support options are available either on individual application, supported by the National Affiliated Societies or by applying to different initiatives supported by the ESSM and open for members to apply upon invitation.

Take Your Chance – Become a Member of ESSM, Now!

Seize the day, or in Latin Carpe diem and become a member of ESSM now, to take all the advantages and benefits of ESSM membership.
There are two levels of ESSM membership available:

ESSM/ISSM Membership
A combined ESSM/ISSM membership (annual fee 160 EUR) for both Sexual Medicine Societies (ESSM/ISSM) including all ESSM and ISSM membership related services, including a subscription to the Journal of Sexual Medicine which is the monthly journal of the ISSM (International) and ESSM (European), and is the leading Journal in the field of Sexual Medicine. In addition there are reduced registration fees for all ISSM/ESSM related congresses.

ESSM only Membership
ESSM only membership (annual fee 50 EUR – reduced to 25 EUR for residents in training) which includes the ESSM official Scientific and Social periodical, the „ESSM Today", full access to the new comprehensive ESSM website:

www.essm.org

(including regularly updated scientific material, monthly updated literature reviews, the most recent guidelines, lecture recordings and presentations from past ESSM congresses), the opportunity to participate in the ESSM educational programs, and to apply for scientific and support grants and a reduced fee for the ESSM annual congress.

Formal ESSM membership applications can either be submitted directly to the ESSM or through one of the national ESSM affiliated societies. The ESSM Executive Committee is responsible for the approval of the membership application.

ESSM Annual Membership Fees (January to December)

Combined ESSM/ISSM Fee incl. JSM Journal	EUR	160
ESSM only Fee	EUR	50*

* A reduced fee EUR 25 is available for residents in training against proof of evidence.

European Society for Sexual Medicine
ESSM SECRETARIAT
Daniela Pajola | Via Ripamonti 129 | 20141 Milano, Italy
phone: +39 02–56601 625 | fax: +39 02–70048 577
email: admin@essm.org

www.essm.org

List of Chairpersons and Presenters

A

Aabakke, A. 17
Abdel Raheem Mohamed, A. M. 23, 26, 39
Ahmadov, I. 14
Aleid, M. 26
Alloussi, S. 32
Almås, E. 19
Amasyali, A. S. 29
Andrews, S. 40
Androshchuk, V. 40, 53
Angelis, A. 18
Angelova, P. 39
Angulo, J. 16, 27, 30
Apolikhin, O. 33
Arbanas, G. 29, 39
Arver, S. 25, 54
Atallah, S. 22
Aversa, A. 25
Aydin, M. 33
Aydos, M. M. 37, 38

B

Baldini, A. 23
Banjac, V. 39
Bannowsky, A. 18, 40
Bayar, G. 26, 31, 33
Bayerle-Eder, M. 29
Behr-Roussel, D. 16
Bekker, M. 31
Beley, S. 54
Bella, T. 15, 24, 53
Bernardo de Paz, A. R. 38
Bernorio, R. 14, 17
Bettocchi, C. 13, 16, 53
Bhatia, V. 31, 33
Bitzer, J. 17, 21, 26, 29
Bivalacqua, T. 16, 23, 29
Bizic, M. 34
Boddi, V. 19, 31, 40
Boeri, L. 28, 29, 31
Bonavigo, T. 38
Bonierbale, M. 21
Bordas, N. 40
Botteon, G. 36
Bou Jaoude, G. 21
Bouman, M.-B. 15, 25
Bozzini, G. 13, 31
Bratvedt Larsen, T. 14
Briedite, I. 37
Briken, P. 20
Brotto, L. A. 15, 19
Buffat, J. 39
Burri, A. 54

C

Cabello, F. S. 20, 28, 37
Calstrom, C. 20
Capdevila, M. 36
Capogrosso, P. 18, 22, 25, 26
Cardoso, P. 14, 25
Carson, C. C. 13
Caruso, S. 17
Castela, A. 30
Castellini, G. 19, 20, 28
Castiglione, F. 16, 33
Cavalcanti, A. 35
Cayan, S. 14, 22, 27
Cellek, S. 15, 16, 25, 32
Chen, B. 33, 35
Chevret Measson, M. 19
Chiappini, S. 28, 40, 53
Cohen-Kettenis, P. T. 21
Colombo, F. 13, 16, 24
Colombo, M. 39
Colson, M. H. 26
Comerma Steffensen, S. 15, 30
Conti, E. 34
Corman, A. 19
Corona, G. 14, 18, 20, 22
Costa, C. 21, 29
Costa, M.P. da 17
Coxon, J. 40
Cruz, N. 14, 21, 26, 53
Cuzin, B. 19, 21, 23, 25

D

Damsted Petersen, C. 17
Dean, J. 21, 27
Del Noco, G. 16
De Luca, F. 40, 53
Desvaux, P. 19
Dewitte, M. 15, 17, 20
Dhejne, C. 21, 28
Di Grazia, M. 36
Dikmans, R. 14
Dimitriadis, F. 30
Dimitropoulos, K. 22, 40, 53
Djordjevic, M. 25, 34
Domagala, Z. 33
Drasa, K. 35
Duarte Abreu, R. 33
Dumbraveanu, I. 33

E

Eardley, I. 14
Egydio, P. 53
El Assar, M. 15
Elaut, E. 14
El Kak, F. 29
Elkowessny, D. 29
Elmeliegy, A. 22
Emilsdottir, M. 20
Erez, G. 28
Etcheverry Giadrosich, B. 40

F

Fabrizi, A. 16
Fahrenkrug, L. 54
Faix, A. 14, 21
Falcone, M. 13, 39
Fasolo, C. B. 17
Federico, S. 36
Fejza, H. 37
Ferenidou, F. 37, 38
Fes, E. 40
Fisher, A. D. 19, 28, 36, 40
Fode, M. 13, 17, 18, 21, 30
Fojecki, G. 25
Fraile, A. 26
Franceschelli, A. 15, 20, 23
Franco, G. 16
Frey, A. 39
Fugl-Meyer, K. 24
Fusco, F. 31, 32

G

Gadalla, A. 22
Gallo, C. 30
Gamet, M. L. 21
Garaffa, G. 16, 25, 54
Garcia Cruz, E. 25, 27
Garcia Gonzalez, L. 31
Garcia Gomez, B. 34
Garcia-Rojo, D. 37, 39
Gargouri, M. M. 31, 34, 37, 40
Geri, V. 40
Giami, A. 21
Gianotten, W. L. 21
Giraldi, A. 19, 24
Giuliano, F. 54
Goddard, J. 34
Gökçe, A. 14

List of Chairpersons and Presenters

Golawski, C. 18
Gonzalez, C. 15
Gonzalez-Cadavid, N. 24, 29
Görts Öberg, K. 28
Gratzke, C. 32
Graziottin, A. 54
Grisolaghi, J. 33
Gruenwald, I. E. 15, 24
Gül, A. 40
Guldager, K. 40
Gunst, A. 37
Gur, S. 30
Gur, U. 39
Gvasalia, B. 15, 23
Gyovai, G. 39

H

Habous, M. 22, 36
Hackett, G. 25, 54
Hakim, L. 15, 53
Hald, G. M. 19
Hall, P. 23
Hananta, I. P. Yuda 29
Hatzichristou, D. 15, 19
Hayek, S. 40
Heald, A. 18
Hedlund, P. 27
Hellstrom, W. J. G. 23, 32
Herwig, R. 13, 34
Ho, C. 27, 35
Højgard, A. 17
Holmberg, M. 27
Huhtaniemi, I. 27, 28
Hulter, B. 29

I

Iacono, F. 22, 30
Ibishev, K. 22, 36
Incrocci, L. 21, 30
Ioakeimidis, N. 27

J

Jannini, E. A. 54
Janssen, P. 54
Jensen, C. F. Skjoedt 36
Jern, P. 22, 54
Jonusiene, G. 20

K

Kadioglu, A. 14, 21, 53
Kaka, D. 33
Kalyvianakis, D. 18
Kamenov, Z. A. 25
Kamnerdsiri, A. 40
Kendirci, M. 15
Khelaia, A. 25, 31, 35, 37, 39
Kirana, P.-S. 17, 20, 27
Kirkeby, H. J. 26, 54
Kitrey, N. 40
Klein, V. 34
Knigavko, O. 36
Kocaturk, A. 14, 37
Kojovic, V. 15
Konstantinidis, K. 22, 33
Kopa, Z. 14, 27
Krakhotkin, D. 22, 40
Krasnyak, S. 33
Kristensen, E. 14
Krüger, T. 24
Krychman, M. 14, 37
Kuehhas, F. 13, 15, 39
Kunelaki, R. 20, 39
Kuwaijo, N. 23, 35

L

La Croce, G. 14
Landmark, B. 20
La Pera, G. 17
Larsen, S. 23
Leffler, C. 39
Leibar, A. 25
Lesnicka, A. 39
Leupin, M. 16
Littara, A. 53
Longhi, E. V. 16
Lopes, S. 34, 39
Lotti, F. 18, 22, 26, 27
Louro, N. 25
Lowenstein, L. 17, 26, 29
Lukacova, V. 39
Lund, L. 31
Luria, M. 14, 17, 40

M

Maatouk, I. 40
Maggi, M. 20, 22, 25
Markos, A. R. 17
Marroig, B. 35
Marshania, Z. 14
Martinez-Salamanca, J. I. 25, 26, 31, 53
Martin-Morales, A. 33
Martin Vauzour, P. 21
Maseroli, E. 18, 22, 27, 33, 35, 40
Mateus, M. 31
Matulevicius, V. 38
Matuleviciute, I. 38
Mavilla, L. 13
McCool, M. 29, 38
McDonald, C. 29
McMahon, C. G. 30, 54
Medina-Polo, J. 35
Milkin, B. 39
Milsom, I. 31
Mintziori, G. 17
Miranda, A. 35
Mirone, V. 54
Moiso, A. 23
Molaei Nezhad, M. 29
Moncada, I. 53
Mondaini, N. 17
Morel-Journel, N. 13, 23, 25
Morgentaler, A. 22, 28
Morone, F. 34
Morton, S. 31
Müller, A. 15
Muin, D. A. 29, 40
Mulhall, J. P. 16
Multescu, R. 36

N

Nappi, R. E. 31
Negro, C. L. A. 23
Nersisyan, N. 39
Nieder, T. O. 21, 28
Nigam, R. 14
Nobre, P. 17
Nowosielski, K. 19

O

Oelke, M. 32
Ofer, Y. 39
Ohl, D. 27, 53, 54
Oliveira, V. 25
Osmonov, D. 23, 54
Østergren, P. 30, 31, 40
Ozer, M. 25

P

Palamara, C. 13
Palmas, A. 39
Palumbo, F. 16
Pandey, S. 31, 35, 39
Pappalardo, D. 33

List of Chairpersons and Presenters

Pastore, A. L. 18, 26
Pedersen, M. B. 18
Peleg Nesher, S. 36
Peleg-Sagy, T. 37
Pereira, B. 25
Pescatori, E. 16, 23, 53
Pirelli Benestad, E. E. 28, 36
Pokorny, P. 27
Polloni, G. 29
Porst, H. 24, 32, 53, 54
Poyato Galan, J. M. 31
Pozarskis, A. 39
Prieto, R. 25
Prunas, A. 28, 33
Puigvert Martínez, A. M. 25

Q

Quaade, M. 33

R

Ralph, D. 13, 14, 16, 53, 54
Rastrelli, G. 22, 35
Rathenborg, J. 37
Ravnik-Oblak, M. 39
Reisman, Y. 17, 21, 29, 53
Renca, S. 39
Ribeiro, M. 14
Rizk, S. L. L. 38
Robles, J. E. 40
Rokkas, K. 22, 33
Romaniuk, M. 23, 26, 31, 39
Romashchenko, O. 38
Romero Otero, J. 26, 31, 53, 54
Rosselló, M. 34
Rossi, R. 16, 17
Ruf, C. 17
Ruffo, A. 22, 30

S

Saad, F. 27, 33
Salas Sironvalle, M. 34
Salonia, A. 18, 54
Sansalone, S. 34, 53
Santiago, M. 34
Sarquella, J. 25, 53
Sartorius, G. 30
Sayin, U. 14, 37
Schillebeeckx, C. J. M. 39
Schmiegelow, A. 18
Schultz, A. 18
Scroppa, F. 17
Sedigh, O. 13, 25
Sempels, M. 13
Serefoglu, E. C. ..... 13, 30, 35, ... 40, 54
Serino, A. 14, 26, 34, 36
Shaeer, O. 15, 28
Shechter, A. 21, 28, 39
Shugusheva, L. 37
Silva, A. 36, 39
Skowronski, D. P. 37
Sola, I. 25
Sønksen, J. 13, 19, 21, 27
Soos, Z. B. 39
Soulier, V. 40
Stanojevic, N. 23, 27, 34
Starowicz, M. L. 24
Stebbeds, W. 24, 30
Stenyaeva, N. 29, 37
Sundberg, M. 38

T

Tal, R. 27
Talseth, T. 23
Tankred, B. 40
Teixeira, A. S. 39
Tekiner, H. 37
Terrier, J.-E. 13
Thomas, C. 36
Timpano, M. 23
Tomada, I. 27
Tomada, N. 26, 27
Tripodi, F. 17, 19, 23
Trotta, D. 17
T'Sjoen, G. 21
Turcan, P. 36

U

Ückert, S. 15
Uvin, P. 30

V

van de Grift, T. 28
van der Sluis, W. 28, 36
van Renterghem, K. 30
Vansintejan, J. 28
Vardi, Y. 31
Velilla, P. 33
Vendeira, P. 14, 26, 28
Ventimiglia, E. 26, 35, 40
Vermeulen, P. 37
Verze, P. 17, 26
Vignozzi, L. 15, 16, 20, 21, 30
Viladoms, J. 25
Vint, R. 34
Virag, R. 54
Vlachopoulos, C. 18
Vozmediano Chicharro, R. 33

W

Wåhlin-Jacobsen, S. 17, 29
Waldinger, M. D. 13, 24, 26
Wang, H. 33, 35
Wardak, S. 34
Wellings, K. 14
Weyne, E. 13, 16, 29, 40
Willans, A. 31
Wismeijer, A. 20
Wylie, K. 17

Y

Yaman, O. 32, 54
Yap, T. 15, 34
Yavuz, A. 40
Yilmaz, D. 15, 30
Ying-Li, C. 26

Z

Zacharakis, E. 13, 23, 34, 54
Zegura, I. 36
Zhang, T. 35
Zitzmann, M. 28

Low testosterone?



TESTIM restores testosterone levels, producing significant improvement in sexual function and mood as well as increased BMD and improved lean body mass[1]

Testim® 50mg **gel**
testosterone

Abbreviated Prescribing Information

Prescribing Information: Testim 50mg Gel. Testim is a clear to translucent gel. One tube of 5 g gel contains 50 mg testosterone. Indication: Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests. **Dosage and administration:** Recommended starting dose: One tube of 5 g gel daily. If serum testosterone levels are below the normal range, the dose may be increased from 50 mg (one tube) to 100 mg (two tubes) once daily. Once opened apply the entire content of the tube immediately to clean dry intact skin of the shoulders and/or upper arms, preferably in the morning. Wash hands immediately after use. Do not apply to the genital area. Not for use in children. Not clinically evaluated in males less than 18 years of age. **Contraindications:** Androgens are contraindicated in men with carcinoma of the breast or known or suspected carcinoma of the prostate. Hypersensitivity to testosterone (synthesised from soy) or to any of the excipients. **Pregnancy and lactation:** Testim is not indicated for women and must not be used in pregnant or breastfeeding women. Pregnant women must avoid skin contact with Testim application sites. **Warnings and precautions:** Prior to therapy, the risk of prostate cancer must be excluded. Examine breast and prostate gland at least yearly and twice yearly in elderly or at risk patients (those with clinical or familial factors). Monitor serum calcium levels in patients with skeletal metastases at risk of hypercalcaemia/hypercalcuria. Testosterone may cause oedema with or without congestive cardiac failure in patients with severe cardiac, hepatic or renal insufficiency. In this case, stop treatment immediately. Use with caution in patients with hypertension, ischemic heart disease, epilepsy, and migraine. Possible increased risk of sleep apnoea in patients who are obese or with chronic respiratory disease. Improved insulin sensitivity may occur. Irritability, nervousness, weight gain, prolonged or frequent erections may indicate excessive androgen exposure requiring dosage adjustment. If severe application site reaction occurs, discontinue treatment if necessary. Periodically monitor testosterone concentrations, full blood count, lipid profile, and liver function. Testosterone may produce a positive reaction in an anti-doping test. Not for use in women. The gel may be transferred to others by skin to skin contact, which could lead to adverse reactions (inadvertent androgenisation) by repeated contact. Inform the patient about the transfer risk, which can be prevented by covering or washing the site before contact. Testim gel should not be prescribed for patients who may not comply with safety instructions (e.g. severe alcoholism, drug abuse, severe psychiatric disorders). The content of the tube is flammable. Testim contains propylene glycol which may cause skin irritation. **Interactions:** Interactions have been reported with oral anticoagulants, ACTH, corticosteroids and propranolol. Laboratory tests have shown that androgens may decrease levels of thyroxine-binding globulin. **Undesirable effects:** Common (1% to <10%): Application site reactions (rash, erythema, pruritus), increased PSA, hypertension worsened, acne, headache, increased haematocrit, increased red blood cell count and increased haemoglobin. Uncommon (0.1% to <1%): Hot flushes/flushing, pruritus and peripheral oedema. Very rare (<0.01% to not known): Azoospermia. Gynaecomastia may uncommonly develop and persist. Other known reactions to testosterone are: Prostate cancer, electrolyte changes, decreased libido, anxiety, emotional liability, generalized paresthesia, nausea, jaundice and liver function test abnormalities, hirsutism, alopecia, seborrhoea, muscle cramps, increased frequency of erections, priapism, prostate abnormalities, altered blood lipid levels (including reduction of HDL cholesterol), and weight gain. Please refer to the Summary of Product Characteristics for the full safety information. **Overdose:** Reports describing overdose have included doses up to 150 mg testosterone. No dose limiting toxicity has been reported from these spontaneous cases. **Presentation:** Testim is supplied as a Carton containing 30 x 5g tubes. **Price:** £32.00. **Legal classification:** POM. **PL Number:** 03194/0105. **Please refer to the Summary of Product Characteristics for full prescribing information. Company name and address:** Ferring Pharmaceuticals Ltd., The Courtyard, Waterside Drive, Langley, Berks, SL3 6EZ. **Date of Preparation: August 2009**

Reference: 1. Dean J *et al.* Rev Urol 2004;6(Suppl 6):S22-29.

Prescribing information may differ in each country.

Testim is not approved in all European markets. Testim is a registered trademark of Auxilium Pharmaceuticals, Inc.

FERRING
PHARMACEUTICALS

Date of preparation: October 2014 TM/946/2014/ECO (1)

www.essm.org